Web notes  

May 2016
PUBLICATIONS - Back

Oncology Archives

1. Akinboye ES, Brennen WN, Rosen DM, Bakare O, Denmeade SR. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy. Prostate. 2016 Feb 2. doi: 10.1002/pros.23162. [Epub ahead of print]
Key words: emetine, enzymatic, fibroblast, peptidase
http://www.ncbi.nlm.nih.gov/pubmed/26835873

2. Cooper TM, Cassar J, Eckroth E, Malvar J, Sposto R, Gaynon P, Chang BH, Gore L, August K, Pollard JA, Dubois SG, Silverman LB, Oesterheld J, Gammon G, Magoon D, Annesley CE, Brown PA. A Phase I study of quizartinib combined with chemotherapy in relapsed childhood leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Clin Cancer Res. 2016 Feb 26. pii: clincanres.1998.2015. [Epub ahead of print]
Key words: leukemia, lymphoma, quizartinib
http://www.ncbi.nlm.nih.gov/pubmed/26920889

3. Faisal F, Tsai HL, Blackford A, Olino K, Xia C, De Jesus-Acosta A, Le DT, Cosgrove D, Azad N, Rasheed Z, Diaz LA Jr, Donehower R, Laheru D, Hruban RH, Fishman EK, Edil BH, Schulick R, Wolfgang C, Herman J, Zheng L. Longer course of induction chemotherapy followed by chemoradiation favors better survival outcomes for patients with locally advanced pancreatic cancer. Am J Clin Oncol. 2016 Feb;39(1):18-26. doi: 10.1097/COC.0000000000000022.
Key words: pancreatic cancer, chemoradiation, survival, chemotherapy
http://www.ncbi.nlm.nih.gov/pubmed/24351782

4. Fu T, Pappou EP, Guzzetta AA, Calmon Mde F, Sun L, Herrera A, Li F, Wolfgang CL, Baylin SB, Iacobuzio-Donahue CA, Tong W, Ahuja N. IGFBP-3 gene methylation in primary tumor predicts recurrence of stage ii colorectal cancers. Ann Surg. 2016 Feb;263(2):337-44. doi: 10.1097/SLA.0000000000001204.
Key words: colorectal cancer, methylation
http://www.ncbi.nlm.nih.gov/pubmed/25822686

5. Housseau F, Wu S, Wick EC, Fan H, Wu X, Llosa NJ, Smith KN, Tam A, Ganguly S, Wanyiri JW, Iyadorai T, Malik AA, Roslani AC, Vadivelu JS, Van Meerbeke S, Huso DL, Pardoll DM, Sears CL. Redundant innate and adaptive sources of IL-17 production drive colon tumorigenesis. Cancer Res. 2016 Feb 15. pii: canres.0749.2015. [Epub ahead of print]
Key words: colon, redundant, tumorigenesis
http://www.ncbi.nlm.nih.gov/pubmed/26880802

6. Izumchenko E, Meir J, Bedi A, Wysocki PT, Hoque M, Sidransky D. Patient derived xenografts as tools in pharmaceutical development. Clin Pharmacol Ther. 2016 Feb 13. doi: 10.1002/cpt.354. [Epub ahead of print]
Key words: xenografts, pharmaceutical development
http://www.ncbi.nlm.nih.gov/pubmed/26874468

7. Jhaveri DT, Kim MS, Thompson ED, Huang L, Sharma R, Klein AP, Zheng L, Le DT, Laheru DA, Pandey A, Jaffee EM, Anders RA. Using quantitative seroproteomics to identify antibody biomarkers in pancreatic cancer. Cancer Immunol Res. 2016 Mar;4(3):225-33. doi: 10.1158/2326-6066.CIR-15-0200-T. Epub 2016 Feb 3.
Key words: seroproteomics, pancreatic cancer, antibodies
http://www.ncbi.nlm.nih.gov/pubmed/26842750

8. Long SY, Latimer EM, Hayward GS. Review of elephant endotheliotropic herpesviruses and acute hemorrhagic disease. ILAR J. 2016 Feb 24;56(3):283-96. doi: 10.1093/ilar/ilv041.
Key words: herpesviruses, elephant, hemorrhagic
PubMed PMID: 26912715; PubMed Central PMCID: PMC4765743.
http://www.ncbi.nlm.nih.gov/pubmed/26912715

9. Roberts NJ, Norris AL, Petersen GM, Bondy ML, Brand R, Gallinger S, Kurtz RC, Olson SH, Rustgi AK, Schwartz AG, Stoffel E, Syngal S, Zogopoulos G, Ali SZ, Axilbund J, Chaffee KG, Chen YC, Cote ML, Childs EJ, Douville C, Goes FS, Herman JM, Iacobuzio-Donahue C, Kramer M, Makohon-Moore A, McCombie RW, McMahon KW, Niknafs N, Parla J, Pirooznia M, Potash JB, Rhim AD, Smith AL, Wang Y, Wolfgang CL, Wood LD, Zandi PP, Goggins M, Karchin R, Eshleman JR, Papadopoulos N, Kinzler KW, Vogelstein B, Hruban RH, Klein AP. Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov. 2016 Feb;6(2):166-75. doi: 10.1158/2159-8290.CD-15-0402. Epub 2015 Dec 9.
Key words: pancreatic cancer, familial, sequencing, genome
http://www.ncbi.nlm.nih.gov/pubmed/26658419

10 Viúdez A, Carvalho FL, Maleki Z, Zahurak M, Laheru D, Stark A, Azad NZ, Wolfgang CL, Baylin S, Herman JG, De Jesus-Acosta A. A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET). Oncotarget. 2016 Feb 17. doi: 10.18632/oncotarget.7436. [Epub ahead of print]
Key words: pancreatic cancer, recurrence, immunohistochemistry
http://www.ncbi.nlm.nih.gov/pubmed/26894863

1. Armstrong AJ, Halabi S, Healy P, Lee WR, Koontz BF, Moul JW, Mundy K, Creel P, Wood S, Davis K, Carducci MA, Stein M, Hobbs C, Reimer B, Nguyen M, Anand M, Bratt L, Kim S, Tran PT, George DJ; Department of Defense Prostate Cancer Clinical Trials Consortium (DOD PCCTC). A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. Prostate Cancer Prostatic Dis. 2016 Mar;19(1):100-6. doi: 10.1038/pcan.2015.59. Epub 2016 Jan 12.
Key words: docetaxel, prednisone, prostatectomy, radiation
http://www.ncbi.nlm.nih.gov/pubmed/26754260

2. Brennen WN, Kisteman LN, Isaacs JT. Rapid selection of mesenchymal stem and progenitor cells in primary prostate stromal cultures. Prostate. 2016 Jan 6. doi: 10.1002/pros.23145. [Epub ahead of print]
Key words: stromal, progenitor, mesenchymal
http://www.ncbi.nlm.nih.gov/pubmed/26732992

3. Cidado J, Wong HY, Rosen DM, Cimino-Mathews A, Garay JP, Fessler AG, Rasheed ZA, Hicks J, Cochran RL, Croessmann S, Zabransky DJ, Mohseni M, Beaver JA, Chu D, Cravero K, Christenson ES, Medford A, Mattox A, De Marzo AM, Argani P, Chawla A, Hurley PJ, Lauring J, Park BH. Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. Oncotarget. 2016 Jan 28. doi: 10.18632/oncotarget.7057. [Epub ahead of print]
Key words: Ki-67, stem cells, proliferation
http://www.ncbi.nlm.nih.gov/pubmed/26823390

4. Leong WY, Guo H, Ma O, Huang H, Cantor AB, Friedman AD. Runx1 Phosphorylation by Src Increases Trans-activation via Augmented Stability, Reduced Histone Deacetylase (HDAC) Binding, and Increased DNA Affinity, and Activated Runx1 Favors Granulopoiesis. J Biol Chem. 2016 Jan 8;291(2):826-36. doi: 10.1074/jbc.M115.674234. Epub 2015 Nov 23.
Key words: deacetylase, phosphorylation, granulopoiesis
http://www.ncbi.nlm.nih.gov/pubmed/26598521

5. Merino VF, Nguyen N, Jin K, Sadik H, Cho S, Korangath P, Han L, Foster YM, Zhou XC, Zhang Z, Connolly R, Stearns V, Ali SZ, Adams C, Chen Q, Pan D, Huso DL, Ordentlich P, Brodie A, Sukumar S. Combined treatment with epigenetic, differentiating, and chemotherapeutic agents cooperatively targets tumor-initiating cells in triple negative breast cancer. Cancer Res. 2016 Jan 19. pii: canres.1619.2015. [Epub ahead of print]
Key words: breast cancer, triple negative, initiating, combined
http://www.ncbi.nlm.nih.gov/pubmed/26787836

6. Reiss KA, Rangachari D, Cosgrove D, Wilky B, Donehower R. Growing pains: a simulation-based curriculum for improving the transition to hematology/oncology fellowship. J Cancer Educ. 2016 Jan 15. [Epub ahead of print]
Key words: transition, improving, curriculum, fellowship
http://www.ncbi.nlm.nih.gov/pubmed/26768145

7. Strowd RE, Abuali I, Ye X, Lu Y, Grossman SA. The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. J Neurooncol. 2016 Jan 4. [Epub ahead of print]
Key words: temozolomide, astrocytoma, survival
http://www.ncbi.nlm.nih.gov/pubmed/26729269

8.Thompson E, Taube JM, Elwood H, Sharma R, Meeker A, Warzecha HN, Argani P, Cimino-Mathews A, Emens LA. The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol. 2016 Jan 15. doi: 10.1038/modpathol.2015.158. [Epub ahead of print]
Key words: microenvironment, breast cancer, ductal carcinoma
http://www.ncbi.nlm.nih.gov/pubmed/26769139

1. Chung CH, Rudek MA, Kang H, Marur S, John P, Tsottles N, Bonerigo S, Veasey A, Kiess A, Quon H, Cmelak A, Murphy BA, Gilbert J. A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma. Oral Oncol. 2016 Feb;53:54-9. doi: 10.1016/j.oraloncology.2015.11.020. Epub 2015 Dec 17.
Key words: ABCB1; Afatinib; Carboplatin; Efficacy; Head and neck squamous cell carcinoma; Paclitaxel; Phase I trial; Toxicity
http://www.ncbi.nlm.nih.gov/pubmed/26705063

2. Karp JE, Wolff AC. Cancer susceptibility genes and their potential implication regarding systemic therapy for early-stage breast cancer. Cancer. 2016 Jan 15;122(2):178-180. doi: 10.1002/cncr.29613. Epub 2015 Dec 7.
Key words: breast cancer, genes, systemic therapy
http://www.ncbi.nlm.nih.gov/pubmed/26642256

3. Murtola T, Gurel B, Umbehr M, Lucia MS, Thompson IM Jr, Goodman PJ, Kristal AR, Parnes HL, Lippman SM, Sutcliffe S, Peskoe SB, Barber JR, Drake CG, Nelson WG, De Marzo AM, Platz EA. Inflammation in benign prostate tissue and prostate cancer in the finasteride arm of the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2015 Dec 29. pii: cebp.0987.2015. [Epub ahead of print]
Key words: prostate cancer, finasteride
http://www.ncbi.nlm.nih.gov/pubmed/26715424

4. Sutcliffe S, Nevin RL, Pakpahan R, Elliott DJ, Langston ME, De Marzo AM, Gaydos CA, Isaacs WB, Nelson WG, Sokoll LJ, Walsh PC, Zenilman JM, Cersovsky SB, Platz EA. Infectious mononucleosis, other infections, and prostate-specific antigen concentration as a marker of prostate involvement during infection. Int J Cancer. 2015 Dec 17. doi: 10.1002/ijc.29966. [Epub ahead of print]
Key words: Infectious mononucleosis; epidemiology; infection; prostate cancer; prostate-specific antigen
http://www.ncbi.nlm.nih.gov/pubmed/26678984

5. Wong HY, Wang GM, Croessmann S, Zabransky DJ, Chu D, Garay JP, Cidado J, Cochran RL, Beaver JA, Aggarwal A, Liu ML, Argani P, Meeker A, Hurley PJ, Lauring J, Park BH. TMSB4Y is a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancer. Oncotarget. 2015 Dec 23. doi:10.18632/oncotarget.6743. [Epub ahead of print]
Key words: TMSB4Y; Y chromosome; cancer genetics; male breast cancer; tumor suppressor
http://www.ncbi.nlm.nih.gov/pubmed/26702755

6. Zong JC, Heaggans SY, Long SY, Latimer EM, Nofs SA, Bronson E, Casares M, Fouraker MD, Pearson VR, Richman LK, Hayward GS. Detection of quiescent infections with multiple elephant endotheliotropic Herpesviruses EEHV2, EEHV3, EEHV6 and EEHV7 within lymphoid lung nodules or lung and spleen tissue samples from five asymptomatic adult African elephants. J Virol. 2015 Dec 30. pii: JVI.02936-15. [Epub ahead of print]
Key words: endotheliotropic Herpesviruses, lung nodules, lung tissue, spleen tissue, elephant
http://www.ncbi.nlm.nih.gov/pubmed/26719245

1. Noonan KA, Borrello IM. Marrow infiltrating lymphocytes: their role in adoptive immunotherapy. Cancer J. 2015 Nov-Dec;21(6):501-5. doi: 10.1097/PPO.0000000000000159.
Key words: lymphocytes, immunotherapy, marrow
http://www.ncbi.nlm.nih.gov/pubmed/26588683

2. Poirier JT, Gardner EE, Connis N, Moreira AL, de Stanchina E, Hann CL, Rudin CM. DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. Oncogene. 2015 Nov 26;34(48):5869-78. doi: 10.1038/onc.2015.38. Epub 2015 Mar 9.
Key words: lung cancer, EZH2, methylation
http://www.ncbi.nlm.nih.gov/pubmed/25746006

3. Rudek MA, Graham RA, Ratain MJ. Harmonization of renal function assessment is needed during early clinical development of oncology drugs. J Clin Oncol. 2015 Nov 30. pii: JCO642553. [Epub ahead of print]
Key words: harmonization, development, assessment
http://www.ncbi.nlm.nih.gov/pubmed/26628472

4. Schweizer MT, Antonarakis ES. Liquid biopsy: Clues on prostate cancer drug resistance. Sci Transl Med. 2015 Nov 4;7(312):312fs45. doi: 10.1126/scitranslmed.aad4008.
Key words: prostate cancer, drug resistance
http://www.ncbi.nlm.nih.gov/pubmed/26537254

5. Tao JH, Barbi J, Pan F. Hypoxia-inducible factors in T lymphocyte differentiation and function. A review in the theme: cellular responses to hypoxia. Am J Physiol Cell Physiol. 2015 Nov 1;309(9):C580-9. doi: 10.1152/ajpcell.00204.2015. Epub 2015 Sep 9.
Key words: lymphocyte, cellular responses, hypoxia
http://www.ncbi.nlm.nih.gov/pubmed/26354751

6. Wangjam T, Zhang Z, Zhou XC, Lyer L, Faisal F, Soares KC, Fishman E, Hruban RH, Herman JM, Laheru D, Weiss M, Li M, De Jesus-Acosta A, Wolfgang CL, Zheng L. Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns. Oncotarget. 2015 Nov 3;6(34):36903-10. doi: 10.18632/oncotarget.5054.
Key words: pancreatic, recurrence, adenocarcinoma, lung cancer
http://www.ncbi.nlm.nih.gov/pubmed/26372811

7. Zabransky DJ, Yankaskas CL, Cochran RL, Wong HY, Croessmann S, Chu D, Kavuri SM, Red Brewer M, Rosen DM, Dalton WB, Cimino-Mathews A, Cravero K, Button B, Kyker-Snowman K, Cidado J, Erlanger B, Parsons HA, Manto KM, Bose R, Lauring J, Arteaga CL, Konstantopoulos K, Park BH. HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6205-14. doi: 10.1073/pnas.1516853112. Epub 2015 Oct 27.
Key words: signaling, missense, mutations, HER2
http://www.ncbi.nlm.nih.gov/pubmed/26508629

8. Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, DeZern A, Maciejewski JP, List AF, Komrokji RS; MDS Clinical Research Consortium (Funded by Edward P. Evans Foundation). Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better? Am J Hematol. 2015 Nov;90(11):1036-40. doi: 10.1002/ajh.24173.
Key words: stratifying models, myelodysplastic, prognostic value
http://www.ncbi.nlm.nih.gov/pubmed/26284571

1. Amankwah EK, Saenz AM, Hale GA, Brown PA. Association between body mass index at diagnosis and pediatric leukemia mortality and relapse: a systematic review and meta-analysis. Leuk Lymphoma. 2015 Oct 9:1-9. [Epub ahead of print]
Key words: lymphoma, pediatric mortality
http://www.ncbi.nlm.nih.gov/pubmed/26453440

2. Avtanski DB, Nagalingam A, Bonner MY, Arbiser JL, Saxena NK, Sharma D. Honokiol activates LKB1-miR-34a axis and antagonizes the oncogenic actions of leptin in breast cancer. Oncotarget. 2015 Oct 6;6(30):29947-62. doi: 10.18632/oncotarget.4937.
Key words: leptin, breast cancer
http://www.ncbi.nlm.nih.gov/pubmed/26359358

3. Ambady P, Holdhoff M, Bonekamp D, Wong F, Grossman SA. Late relapses in primary CNS lymphoma after complete remissions with high-dose methotrexate monotherapy. CNS Oncol. 2015 Oct 28. [Epub ahead of print]
Key words: relapses, lymphoma, methotrexate
http://www.ncbi.nlm.nih.gov/pubmed/26507609

4. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
Key words: lung cancer, nivolumab, docetaxel, nonsquamous
http://www.ncbi.nlm.nih.gov/pubmed/26412456

5. Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C, Niknafs N, Nesselbush M, Lytle K, Sassi F, Cottino F, Migliardi G, Zanella ER, Ribero D, Russolillo N, Mellano A, Muratore A, Paraluppi G, Salizzoni M, Marsoni S, Kragh M, Lantto J, Cassingena A, Li QK, Karchin R, Scharpf R, Sartore-Bianchi A, Siena S, Diaz LA Jr, Trusolino L, Velculescu VE. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature. 2015 Oct 8;526(7572):263-7. doi: 10.1038/nature14969. Epub 2015 Sep 30.
Key words: EGFR, landscape, colorectal cancer

http://www.ncbi.nlm.nih.gov/pubmed/26416732

6. Cooper SL, Arceci RJ, Gamper CJ, Teachey DT, Schafer ES. Successful Treatment of Recurrent Autoimmune Cytopenias in the Context of Sinus Histiocytosis With Massive Lymphadenopathy Using Sirolimus. Pediatr Blood Cancer. 2015 Oct 9. doi: 10.1002/pbc.25770. [Epub ahead of print]
Key words: cytopenias, sirolimus, treatment, autoimmune
http://www.ncbi.nlm.nih.gov/pubmed/26452062

7. Gaykalova DA, Manola JB, Ozawa H, Zizkova V, Morton K, Bishop JA, Sharma R, Zhang C, Michailidi C, Considine M, Tan M, Fertig EJ, Hennessey PT, Ahn J, Koch WM, Westra WH, Khan Z, Chung CH, Ochs MF, Califano JA. NF-?B and stat3 transcription factor signatures differentiate HPV-positive and HPV-negative head and neck squamous cell carcinoma. Int J Cancer. 2015 Oct 15;137(8):1879-89. doi: 10.1002/ijc.29558. Epub 2015 Jun 23.
Key words: carcinoma, stat3, squamous, transcription
http://www.ncbi.nlm.nih.gov/pubmed/25857630

8. Hurley PJ, Sundi D, Shinder B, Simons B, Hughes RM, Miller RM, Benzon B, Faraj SF, Netto GJ, Vergara IA, Erho N, Davicioni E, Karnes RJ, Yan G, Ewing CM, Isaacs SD, Berman DM, Rider JR, Jordahl KM, Mucci LA, Huang J, An S, Park BH, Isaacs WB, Marchionni L, Ross AE, Schaeffer E. Germline variants in asporin vary by race, modulate the tumor microenvironment and are differentially associated with metastatic prostate cancer. Clin Cancer Res. 2015 Oct 7. pii: clincanres.0256.2015. [Epub ahead of print]
Key words: prostate cancer, microenvironment, modulate
http://www.ncbi.nlm.nih.gov/pubmed/26446945

9. Negi SS, Brown P. Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells. Oncotarget. 2015 Oct 27;6(33):34846-58. doi: 10.18632/oncotarget.5413.
Key words: leukemia, synthesis, rRNA, transient
http://www.ncbi.nlm.nih.gov/pubmed/26472108

10. Qualliotine JR, Mydlarz WK, Chan JY, Zhou X, Wang H, Agrawal N. Comparing staging by positron emission tomography with contrast-enhanced computed tomography and by pathology in head and neck squamous cell carcinoma. J Laryngol Otol. 2015 Oct 22:1-7. [Epub ahead of print]
Key words: tomography, carcinoma, squamous, positron
http://www.ncbi.nlm.nih.gov/pubmed/26490394

11. Soares KC, Rucki AA, Kim V, Foley K, Solt S, Wolfgang CL, Jaffee EM, Zheng L. TGF-? blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner. Oncotarget. 2015 Oct 15. doi: 10.18632/oncotarget.5656. [Epub ahead of print]
Key words: pancreatic tumors, vaccine
http://www.ncbi.nlm.nih.gov/pubmed/26515728

12. Wu X, Zahari MS, Ma B, Liu R, Renuse S, Sahasrabuddhe NA, Chen L, Chaerkady R, Kim MS, Zhong J, Jelinek C, Barbhuiya MA, Leal-Rojas P, Yang Y, Kashyap MK, Marimuthu A, Ling M, Fackler MJ, Merino V, Zhang Z, Zahnow CA, Gabrielson E, Stearns V, Roa JC, Sukumar S, Gill PS, Pandey A. Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways. Oncotarget. 2015 Oct 6;6(30):29143-60. doi: 10.18632/oncotarget.5020.
Key words: phosphotyrosine, breast cancer, tyrosine kynase
http://www.ncbi.nlm.nih.gov/pubmed/26356563

13. Zabransky DJ, Yankaskas CL, Cochran RL, Wong HY, Croessmann S, Chu D, Kavuri SM, Red Brewer M, Rosen DM, Dalton WB, Cimino-Mathews A, Cravero K, Button B, Kyker-Snowman K, Cidado J, Erlanger B, Parsons HA, Manto KM, Bose R, Lauring J, Arteaga CL, Konstantopoulos K, Park BH. HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6205-14. doi: 10.1073/pnas.1516853112. Epub 2015 Oct 27.
Key words: mutations, signaling, missense, oncogenic
http://www.ncbi.nlm.nih.gov/pubmed/26508629

14. Zeidan AM, Sekeres MA, Garcia-Manero G, Steensma DP, Zell K, Barnard J, Al Ali N, Zimmerman C, Roboz G, DeZern A, Nazha A, Jabbour E, Kantarjian H, Gore SD, Maciejewski JP, List A, Komrokji R. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia. 2015 Oct 14. doi: 10.1038/leu.2015.283. [Epub ahead of print]
Key words: leukemia, stratification
http://www.ncbi.nlm.nih.gov/pubmed/26464171

15. Zhu W, Huang P, Macura KJ, Artemov D. Association between breast cancer, breast density, and body adiposity evaluated by MRI. Eur Radiol. 2015 Oct 21. [Epub ahead of print]
Key words: adiposity, breast cancer, density
http://www.ncbi.nlm.nih.gov/pubmed/26489749

1. Beachler DC, Guo Y, Xiao W, Burk RD, Minkoff H, Strickler HD, Cranston RD, Wiley DJ, Jacobson LP, Weber KM, Margolick JB, Sugar EA, Reddy S, Gillison ML, D'Souza G. High oral human papillomavirus type 16 load predicts long-term persistence in individuals with or at risk for HIV infection. J Infect Dis. 2015 Nov 15;212(10):1588-91. doi: 10.1093/infdis/jiv273.
Key words: persistence, hpv, infections, HIV
http://www.ncbi.nlm.nih.gov/pubmed/25954049

2. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643.
Key words: lung cancer, docetaxel, nonsquamous
http://www.ncbi.nlm.nih.gov/pubmed/26412456

3. Cosgrove DP, Reyes DK, Pawlik TM, Feng AL, Kamel IR, Geschwind JF. Open-label single-arm phase ii trial of sorafenib therapy with drug-eluting bead transarterial chemoembolization in patients with unresectable hepatocellular carcinoma: clinical results. Radiology. 2015 Nov;277(2):594-603. doi:
10.1148/radiol.2015142481.
Key words: carcinoma, hepatocellular, chemoembolization
http://www.ncbi.nlm.nih.gov/pubmed/26069923

4. Jackson CM, Kochel CM, Nirschl CJ, Durham NM, Ruzevick J, Alme A, Francica BJ, Elias J, Daniels A, Dubensky TW Jr, Lauer P, Brockstedt D, Baxi EG, Calabresi PA, Taube JM, Pardo CA, Brem H, Pardoll DM, Lim M, Drake CG. Systemic tolerance mediated by melanoma brain tumors is reversible by radiotherapy and vaccination. Clin Cancer Res. 2015 Oct 21. pii: clincanres.1516.2015.
Key words: vaccination, radiotherapy, brain tumor, reversible, melanoma
http://www.ncbi.nlm.nih.gov/pubmed/26490306

5. Li R, Faden DL, Fakhry C, Langelier C, Jiao Y, Wang Y, Wilkerson MD, Pedamallu CS, Old M, Lang J, Loyo M, Ahn SM, Tan M, Gooi Z, Chan J, Richmon J, Wood LD, Hruban RH, Bishop J, Westra WH, Chung CH, Califano J, Gourin CG, Bettegowda C, Meyerson M, Papadopoulos N, Kinzler KW, Vogelstein B, DeRisi JL, Koch WM, Agrawal N. Clinical, genomic, and metagenomic characterization of oral tongue squamous cell carcinoma in patients who do not smoke. Head Neck. 2015 Nov;37(11):1642-9. doi: 10.1002/hed.23807. Key words: metagenomics, squamous, smoke, tongue, carcinoma
http://www.ncbi.nlm.nih.gov/pubmed/24954188

6. Lombardi LR, Kanakry CG, Zahurak M, Durakovic N, Bolaños-Meade J, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Brodsky RA, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L. Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. Leuk Lymphoma. 2015 Oct 12:1-10. [Epub ahead of print]
Key words: cyclophosphamide, busulfan
http://www.ncbi.nlm.nih.gov/pubmed/26292764

7. Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer. Prostate. 2015 Nov;75(15):1814-20. doi: 10.1002/pros.23064.
Key words: prostate cancer, abiraterone, docetaxel
http://www.ncbi.nlm.nih.gov/pubmed/26306637

8. Santa-Maria CA, Blackford AL, Nguyen AT, Skaar TC, Philips S, Oesterreich S, Rae JM, Desta Z, Robarge JD, Henry NL, Storniolo AM, Hayes DF, Blumenthal RS, Ouyang P, Post WS, Flockhart DA, Stearns V. Association of variants in candidate genes with lipid profiles in women with early breast cancer on adjuvant aromatase inhibitor therapy. Clin Cancer Res. 2015 Oct 13. pii: clincanres.1213.2015. [Epub ahead of print]
Key words: lipid profiles, breast cancer, aromatase
http://www.ncbi.nlm.nih.gov/pubmed/26463708

9. Sison EA, Magoon D, Li L, Annesley CE, Romagnoli B, Douglas GJ, Tuffin G, Zimmermann J, Brown P. POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL. Oncotarget. 2015 Oct 13;6(31):30902-18. doi: 10.18632/oncotarget.5094.
Key words: CXCR4, chemotherapy, pediatric
http://www.ncbi.nlm.nih.gov/pubmed/26360610

10. Romano A, Parrinello NL, Consoli ML, Marchionni L, Forte S, Conticello C, Pompa A, Corso A, Milone G, Di Raimondo F, Borrello I. Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents. Ann Hematol. 2015 Nov;94(11):1875-83. doi: 10.1007/s00277-015-2462-4. Epub 2015 Jul 31.
Key words: ISS, multiple myeloma, neutrophil
http://www.ncbi.nlm.nih.gov/pubmed/26223359

11. Zabransky DJ, Yankaskas CL, Cochran RL, Wong HY, Croessmann S, Chu D, Kavuri SM, Red Brewer M, Rosen DM, Dalton WB, Cimino-Mathews A, Cravero K, Button B, Kyker-Snowman K, Cidado J, Erlanger B, Parsons HA, Manto KM, Bose R, Lauring J, Arteaga CL, Konstantopoulos K, Park BH. HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proc Natl Acad Sci U S A. 2015 Oct
27. pii: 201516853. [Epub ahead of print]
Key words: oncogenic signaling, mutations, HER2
http://www.ncbi.nlm.nih.gov/pubmed/26508629

12. Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, DeZern A, Maciejewski JP, List AF, Komrokji RS; MDS Clinical Research Consortium (Funded by Edward P. Evans Foundation). Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better? Am J Hematol. 2015
Nov;90(11):1036-40. doi: 10.1002/ajh.24173.
Key words: myelodysplastic, stratifying
http://www.ncbi.nlm.nih.gov/pubmed/26284571

1. Ball DW, Jin N, Xue P, Bhan S, Ahmed SR, Rosen DM, Schayowitz A, Clark DP, Nelkin BD. Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer. Oncol Rep. 2015 Aug 26. doi: 10.3892/or.2015.4225. [Epub ahead of print]
Key words: thyroid cancer, pazopanib, trametinib
http://www.ncbi.nlm.nih.gov/pubmed/26324075

2. Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, Andresen C, O'Brien JP, Ren M, Funahashi Y, Allison R, Elisei R, Newbold K, Licitra LF, Sherman SI, Ball DW. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer. 2015 Aug 15;121(16):2749-56. doi: 10.1002/cncr.29395. Epub 2015 Apr 24.
Key words: thyroid cancer, lenvatinib, radioiodine
http://www.ncbi.nlm.nih.gov/pubmed/25913680

3. Croessmann S, Wong HY, Zabransky DJ, Chu D, Mendonca J, Sharma A, Mohseni M, Rosen DM, Scharpf RB, Cidado J, Cochran RL, Parsons HA, Dalton WB, Erlanger B, Button B, Cravero K, Kyker-Snowman K, Beaver JA, Kachhap S, Hurley PJ, Lauring J, Park BH. NDRG1 links p53 with proliferation-mediated centrosome homeostasis and genome stability. Proc Natl Acad Sci U S A. 2015 Aug 31. pii: 201503683.
Key words: homeostasis, centrosome, p53
http://www.ncbi.nlm.nih.gov/pubmed/26324937

4. Gorin MA, Rowe SP, Allaf ME, Argani P. Angiomyolipoma with epithelial cysts: Add one to the differential of cystic renal lesions. Int J Urol. 2015 Aug 25. doi: 10.1111/iju.12908. [Epub ahead of print]
Key words: epithelial, renal, cysts, lesions
http://www.ncbi.nlm.nih.gov/pubmed/26303457

5. Haffner MC, Weier C, Xu M, Vaghasia A, Gürel B, Gümü?kaya B, Esopi DM, Fedor H, Tan HL, Kulac I, Hicks J, Isaacs WB, Lotan TL, Nelson WG, Yegnasubramanian S, De Marzo AM. Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization. J Pathol. 2015 Aug 31. doi: 10.1002/path.4628. [Epub ahead of print]
Key words: adenocarcinoma, glandular, retrograde, colonization
http://www.ncbi.nlm.nih.gov/pubmed/26331372

6. Hurley PJ, Hughes RM, Simons B, Huang J, Miller RM, Shinder B, Haffner MC, Esopi D, Kinura Y, Jabbari J, Ross AE, Erho N, Vergara IA, Faraj SF, Davicioni E, Netto GJ, Yegnasubramanian S, An S, Schaeffer E. Androgen Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression. Cancer Res. 2015 Aug 20. pii: canres.0024.2015. [Epub ahead of print]
Key words: SPARCL1, microenvironment
http://www.ncbi.nlm.nih.gov/pubmed/26294211

7. Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2015 Aug 25. doi: 10.1038/nrclinonc.2015.128. [Epub ahead of print] Review.
Key words: haploidentical, HLA, transplantation
http://www.ncbi.nlm.nih.gov/pubmed/26305035

8. Lombardi LR, Kanakry C, Zahurak M, Durakovic N, Bolaños-Meade J, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Brodsky RA, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L. Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. Leuk Lymphoma. 2015 Aug 21:1-30. [Epub ahead of print]
Key words: busulfan, cyclophosphamide
http://www.ncbi.nlm.nih.gov/pubmed/26292764

9. Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer. Prostate. 2015 Aug 26. doi: 10.1002/pros.23064. [Epub ahead of print]
Key words: prostate cancer, abiraterone, docetaxel
http://www.ncbi.nlm.nih.gov/pubmed/26306637

10. Platz EA, Drake CG, Wilson KM, Sutcliffe S, Kenfield SA, Mucci LA, Stampfer MJ, Willett WC, Camargo CA Jr, Giovannucci E. Asthma and risk of lethal prostate cancer in the Health Professionals Follow-Up Study. Int J Cancer. 2015 Aug 15;137(4):949-58. doi: 10.1002/ijc.29463. Epub 2015 Feb 27.
Key words: prostate cancer, asthma
http://www.ncbi.nlm.nih.gov/pubmed/25648070

11. Tao JJ, Visvanathan K, Wolff AC. Long term side effects of adjuvant chemotherapy in patients with early breast cancer. Breast. 2015 Aug 20. pii: S0960-9776(15)00173-3. doi: 10.1016/j.breast.2015.07.035. [Epub ahead of print]
Key words: breast cancer, chemotherapy, side effects
http://www.ncbi.nlm.nih.gov/pubmed/26299406

1. Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 2015 Aug 1;1(5):582-591. doi: 10.1001/jamaoncol.2015.1341.
Key words: prostate cancer, chemotherapy, taxane
http://www.ncbi.nlm.nih.gov/pubmed/26181238

2. Chen D, Nicholas J. Promotion of endoplasmic reticulum-associated degradation of procathepsin D by human Herpesvirus 8-encoded viral interleukin-6. J Virol. 2015 Aug 1;89(15):7979-90. doi: 10.1128/JVI.00375-15. Epub 2015 May 27.
Key words: herpesvirus, interleukin
http://www.ncbi.nlm.nih.gov/pubmed/26018151

3. Childs EJ, Mocci E, Campa D, Bracci PM, Gallinger S, Goggins M, Li D, Neale RE, Olson SH, Scelo G, Amundadottir LT, Bamlet WR, Bijlsma MF, Blackford A, Borges M, Brennan P, Brenner H, Bueno-de-Mesquita HB, Canzian F, Capurso G, Cavestro GM, Chaffee KG, Chanock SJ, Cleary SP, Cotterchio M, Foretova L, Fuchs C, Funel N, Gazouli M, Hassan M, Herman JM, Holcatova I, Holly EA, Hoover RN, Hung RJ, Janout V, Key TJ, Kupcinskas J, Kurtz RC, Landi S, Lu L, Malecka-Panas E, Mambrini A, Mohelnikova-Duchonova B, Neoptolemos JP, Oberg AL, Orlow I, Pasquali C, Pezzilli R, Rizzato C, Saldia A, Scarpa A, Stolzenberg-Solomon RZ, Strobel O, Tavano F, Vashist YK, Vodicka P, Wolpin BM, Yu H, Petersen GM, Risch HA, Klein AP. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Nat Genet. 2015 Aug;47(8):911-6. doi: 10.1038/ng.3341. Epub 2015 Jun 22.
Key words: pancreatic cancer, 1p13, 3q29, 17q25
http://www.ncbi.nlm.nih.gov/pubmed/26098869

4. Geis AL, Fan H, Wu X, Wu S, Huso DL, Wolfe JL, Sears CL, Pardoll DM, Housseau F. Regulatory T cell response to enterotoxigenic Bacteroides fragilis colonization triggers IL-17-dependent colon carcinogenesis. Cancer Discov. 2015 Jul 22. pii: CD-15-0447. [Epub ahead of print]
Key words: colon, enterotoxigenic, bacteroides fragilis
http://www.ncbi.nlm.nih.gov/pubmed/26201900

5. Korangath P, Teo WW, Sadik H, Han L, Mori N, Huijts CM, Wildes F, Bharti S, Zhang Z, Santa-Maria CA, Tsai H, Dang CV, Stearns V, Bhujwalla ZM, Sukumar S. Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate. Clin Cancer Res. 2015 Jul 15;21(14):3263-73. doi: 10.1158/1078-0432.CCR-14-1200. Epub 2015 Mar 26.
Key words: glutamine, breast cancer, aminooxyacetate
http://www.ncbi.nlm.nih.gov/pubmed/25813021

6. Moningi S, Dholakia AS, Raman SP, Blackford A, Cameron JL, Le DT, De Jesus-Acosta AM, Hacker-Prietz A, Rosati LM, Assadi RK, Dipasquale S, Pawlik TM, Zheng L, Weiss MJ, Laheru DA, Wolfgang CL, Herman JM. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience. Ann Surg Oncol. 2015 Jul;22(7):2352-8. doi: 10.1245/s10434-014-4274-5. Epub 2015 Jan 7.
Key words: pancreatic cancer, stereotactic, body radiation
PubMed PMID: 25564157; PubMed Central PMCID: PMC4459890.
http://www.ncbi.nlm.nih.gov/pubmed/25564157

7. Nash SH, Schenk JM, Kristal AR, Goodman PJ, Lucia MS, Parnes HL, Thompson IM, Lippman SM, Song X, Gurel B, De Marzo A, Platz EA. Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila). 2015 Jul;8(7):590-6. doi: 10.1158/1940-6207.CAPR-14-0398. Epub 2015 Apr 29.
Key words: inflammation, prostate cancer, phospholipid
PubMed PMID: 25926387; PubMed Central PMCID: PMC4491033.
http://www.ncbi.nlm.nih.gov/pubmed/25926387

8. Negi SS, Brown P. rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis. Oncotarget. 2015 Jul 20;6(20):18094-104.
Key words: leukemia, lymphoblastic, apoptosis
PubMed PMID: 26061708.
http://www.ncbi.nlm.nih.gov/pubmed/26061708

9. Sausen M, Phallen J, Adleff V, Jones S, Leary RJ, Barrett MT, Anagnostou V, Parpart-Li S, Murphy D, Kay Li Q, Hruban CA, Scharpf R, White JR, O'Dwyer PJ, Allen PJ, Eshleman JR, Thompson CB, Klimstra DS, Linehan DC, Maitra A, Hruban RH, Diaz LA Jr, Von Hoff DD, Johansen JS, Drebin JA, Velculescu VE. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun. 2015 Jul 7;6:7686. doi: 10.1038/ncomms8686.
Key words: pancreatic cancer, implications, genomic, alterations
http://www.ncbi.nlm.nih.gov/pubmed/26154128

10. Stanley SE, Armanios M. The short and long telomere syndromes: paired paradigms for molecular medicine. Curr Opin Genet Dev. 2015 Jul 28;33:1-9. doi: 10.1016/j.gde.2015.06.004. [Epub ahead of print] Review.
Key words: syndrome, long, telomere, molecular
http://www.ncbi.nlm.nih.gov/pubmed/26232116

1. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD,
Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP,Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wigginton JM, Hellmann MD, Kollia GD,Gupta AK, Brahmer JR. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015 Jun 20;33(18):2004-12. doi: 10.1200/JCO.2014.58.3708.
Key words: lung cancer, nivolumab
http://www.ncbi.nlm.nih.gov/pubmed/25897158

2. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.
Key words: PD-1, mismatch, repair
http://www.ncbi.nlm.nih.gov/pubmed/26028255

3. Markowski MC, Eisenberger M, Zahurak M, Epstein JI, Paller C. Sarcomatoid Carcinoma of the Prostate: Retrospective Review of a Case Series from Johns Hopkins Hospital. Urology. 2015 Jun 27. pii: S0090-4295(15)00597-X. doi: 10.1016/j.urology.2015.06.011. [Epub ahead of print]
Key words: prostate cancer, carcinoma, case series
http://www.ncbi.nlm.nih.gov/pubmed/26126695

4. Maughan BL, Antonarakis ES. Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opin Pharmacother. 2015 Jul;16(10):1521-37. doi: 10.1517/14656566.2015.1055249. Epub 2015 Jun 12.
Key words: prostate cancer, androgen
http://www.ncbi.nlm.nih.gov/pubmed/26067250

5. Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, Luo J, Antonarakis ES. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann Oncol. 2015 Jun 27. pii: mdv282. [Epub ahead of print]
Key words: prostate cancer, AR-V7
http://www.ncbi.nlm.nih.gov/pubmed/26117829

6. Patel MA, Pardoll DM. Concepts of immunotherapy for glioma. J Neurooncol. 2015 Jul;123(3):323-30. doi: 10.1007/s11060-015-1810-5. Epub 2015 Jun 13.
Key words: immunotherapy, glioma
http://www.ncbi.nlm.nih.gov/pubmed/26070552

7. Rajeshkumar NV, Dutta P, Yabuuchi S, de Wilde RF, Matrinez GV, Le A, Kamphorst JJ, Rabinowitz JD, Jain SK, Hidalgo M, Dang CV, Gillies RJ, Maitra A. Therapeutic targeting of the Warburg effect in pancreatic cancer relies on an absence of p53 function. Cancer Res. 2015 Jun 25. pii: canres.0108.2015. [Epub ahead of print]
Key words: Warburg, pancreatic cancer, p53
http://www.ncbi.nlm.nih.gov/pubmed/26113084

8. Wang Y, Springer S, Mulvey CL, Silliman N, Schaefer J, Sausen M, James N, Rettig EM, Guo T, Pickering CR, Bishop JA, Chung CH, Califano JA, Eisele DW, Fakhry C, Gourin CG, Ha PK, Kang H, Kiess A, Koch WM, Myers JN, Quon H, Richmon JD, Sidransky D, Tufano RP, Westra WH, Bettegowda C, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelstein B, Agrawal N. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med. 2015 Jun 24;7(293):293ra104. doi: 10.1126/scitranslmed.aaa8507.
Key words: HPV, squamous, saliva, plasma
http://www.ncbi.nlm.nih.gov/pubmed/26109104

9. Woodard C, Liao G, Goodwin CR, Hu J, Xie Z, Dos Reis TF, Newman R, Rho H, Qian J, Zhu H, Hayward SD. A Screen for ERK Primed GSK-3 Substrates Identifies the p53 Inhibitor iASPP. J Virol. 2015 Jun 24. pii: JVI.01072-15. [Epub ahead of print]
Key words: ERK, p53, GSK-3
http://www.ncbi.nlm.nih.gov/pubmed/26109723

1. Beachler DC, Guo Y, Xiao W, Burk RD, Minkoff H, Strickler HD, Cranston RD, Wiley DJ, Jacobson LP, Weber KM, Margolick JB, Sugar EA, Reddy S, Gillison ML, D'Souza G. High oral HPV16 viral load predicts long-term persistence in HIV-infected and at risk HIV-uninfected individuals. J Infect Dis. 2015 May 7. pii: jiv273. [Epub ahead of print]
Key words: HPV16, viral load, HIV infection
http://www.ncbi.nlm.nih.gov/pubmed/25954049

2. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015 May 31. [Epub ahead of print]
Key words: nivolumab, docetaxel, lung cancer
http://www.ncbi.nlm.nih.gov/pubmed/26028407

3. Chen D, Nicholas J. Promotion of endoplasmic reticulum-associated degradation of pro-cathepsin d by human Herpesvirus 8-encoded viral interleukin-6. J Virol. 2015 May 27. pii: JVI.00375-15. [Epub ahead of print]
Key words: pro-cathepsin d, Herpesvirus 8, endoplasmic reticulum, interleukin-6
http://www.ncbi.nlm.nih.gov/pubmed/26018151

4. Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015 May;3(5):436-443. Review.
Key words: immunotherapy, chemotherapy, cancer
http://www.ncbi.nlm.nih.gov/pubmed/25941355

5. Joshu CE, Peskoe SB, Heaphy CM, Kenfield SA, Van Blarigan EL, Mucci LA, Giovannucci EL, Stampfer MJ, Yun G, Lee TK, Hicks JL, De Marzo AM, Meeker AK, Platz EA. Pre-diagnostic obesity and physical inactivity are associated with shorter telomere length in prostate stromal cells. Cancer Prev Res (Phila). 2015 May 19. pii: canprevres.0097.2015. [Epub ahead of print]
Key words: obesity, telomere, stromal cells, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/25990087

6. Kelly RJ, Forde PM, Elnahal SM, Forastiere AA, Rosner GL, Smith TJ. Patients and physicians can discuss costs of cancer treatment in the clinic. J Oncol Pract. 2015 May 26. pii: JOP.2015.003780. [Epub ahead of print]
Key words: patients, physicians, cancer, costs
http://www.ncbi.nlm.nih.gov/pubmed/26015459

7. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015 May 30. [Epub ahead of print]
Key words: tumors, PD-1 blockade, mismatch-repair deficiency
http://www.ncbi.nlm.nih.gov/pubmed/26028255

8. Leech M, Morris L, Stewart M, Smith BD, Bashey A, Holland K, Solomon S, Zhang X, Carraway HE, Pratz K, Gore SD, Zeidan AM. Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapy. Clin Lymphoma Myeloma Leuk. 2015 May;15(5):292-7. doi: 10.1016/j.clml.2014.11.001.
Key words: promyelocytic leukemia, arsenic trioxide, chemotherapy, anthracycline exposure
http://www.ncbi.nlm.nih.gov/pubmed/25499624

9. Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase 2 study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 May 28. pii: haematol.2015.125849. [Epub ahead of print]
Key words: flavorpiridol, cytarabine, mitroxantrone, acute myeloid leukemia
http://www.ncbi.nlm.nih.gov/pubmed/26022709

1. Alder JK, Barkauskas CE, Limjunyawong N, Stanley SE, Kembou F, Tuder RM, Hogan BL, Mitzner W, Armanios M. Telomere dysfunction causes alveolar stem cell failure. Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):5099-104. doi: 10.1073/pnas.1504780112. Epub 2015 Apr 3.
Key words: alveolar, telomere, failure
http://www.ncbi.nlm.nih.gov/pubmed/25840590

2. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP, Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wigginton JM, Hellmann MD, Kollia GD, Gupta AK, Brahmer JR. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015 Apr 20. pii: JCO.2014.58.3708. [Epub ahead of print]
Key words: Nivolumab, lung cancer, survival
http://www.ncbi.nlm.nih.gov/pubmed/25897158

3. Hu C, Dadon T, Chenna V, Yabuuchi S, Bannerji R, Booher R, Strack P, Azad NA, Nelkin BD, Maitra A. Combined inhibition of cyclin-dependent kinases (dinaciclib) and AKT (MK-2206) blocks pancreatic tumor growth and metastases in patient-derived xenograft models. Mol Cancer Ther. 2015 Apr 30. pii: molcanther.0028.2015. [Epub ahead of print]
Key words: AKT, pancreatic cancer, metastases, cyclin
http://www.ncbi.nlm.nih.gov/pubmed/25931518

4. Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, Lutz ER, Solt S, Murphy AL, Skoble J, Lemmens E, Grous J, Dubensky T Jr, Brockstedt DG, Jaffee EM. Safety and survival With GVAX pancreas prime and listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015 Apr 20;33(12):1325-33. doi: 10.1200/JCO.2014.57.4244. Epub 2015 Jan 12.
Key words: pancreatic cancer, listeria, mesothelin
http://www.ncbi.nlm.nih.gov/pubmed/25584002

5. Pardoll DM. Distinct mechanisms of tumor resistance to NK killing: of mice and men. Immunity. 2015 Apr 21;42(4):605-6. doi: 10.1016/j.immuni.2015.04.007.
Key words: Mechanisms, tumor resistance, NK
http://www.ncbi.nlm.nih.gov/pubmed/25902479

6. Peskoe SB, Joshu CE, Rohrmann S, McGlynn KA, Nyante SJ, Bradwin G, Dobs AS, Kanarek N, Nelson WG, Platz EA. Circulating total testosterone and PSA concentrations in a nationally representative sample of men without a diagnosis of prostate cancer. Prostate. 2015 Apr 28. doi: 10.1002/pros.22998. [Epub ahead of print]
Key words: testosterone, prostate cancer, PSA
http://www.ncbi.nlm.nih.gov/pubmed/25919471

7. Rao AD, Sugar EA, Barrett N, Mahesh M, Arceci RJ. The utility of computed tomography in the management of fever and neutropenia in pediatric oncology. Pediatr Blood Cancer. 2015 Apr 30. doi: 10.1002/pbc.25561. [Epub ahead of print]
Key words: neutropenia, pediatric oncology, tomography
http://www.ncbi.nlm.nih.gov/pubmed/25929242

8. Strowd RE 3rd, Abuali IA, Grossman SA. Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma. CNS Oncol. 2015 May;4(3):131-5. doi: 10.2217/cns.15.3. Epub 2015 Apr 23.
Key words: lymphoma, rituximab, crerebrospinal
http://www.ncbi.nlm.nih.gov/pubmed/25905905

9. Wang J, Reiss Binder K, Khatri R, Jaffee E, Laheru D. Immune therapy in GI malignancies: a review. J Clin Oncol. 2015 Apr 27. pii: JCO.2015.60.7879. [Epub ahead of print] Review. PubMed PMID: 25918295.
Key words: GI, immune therapy
http://www.ncbi.nlm.nih.gov/pubmed/25918295

1. Culton DA, McCray SK, Park M, Roberts JC, Li N, Zedek DC, Anhalt GJ, Cowley D, Liu Z, Diaz LA. Mucosal pemphigus vulgaris Anti-Dsg3 IgG are pathogenic to the oral mucosa of humanized Dsg3 mice. J Invest Dermatol. 2015 Feb 19. doi: 10.1038/jid.2015.54. [Epub ahead of print]
Key words: oral mucosa, Dsg3, humanized
http://www.ncbi.nlm.nih.gov/pubmed/25695683

2. Isaacs JT. Lessons learned about prostatic transformation from the age-related methylation of 5?-reductase type 2 gene. Am J Pathol. 2015 Mar;185(3):614-6. doi: 10.1016/j.ajpath.2015.01.001. Epub 2015 Feb 17.
Key words: methylation, transformation, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/25700984

3. Kouo T, Huang L, Pucsek AB, Cao M, Solt S, Armstrong T, Jaffee E. Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells. Cancer Immunol Res. 2015 Feb 17. [Epub ahead of print]
Key words: plasmacytoid, antitumor, galectin-3
http://www.ncbi.nlm.nih.gov/pubmed/25691328

4. Kulac I, Haffner MC, Yegnasubramanian S, Epstein JI, De Marzo AM. Should Gleason 6 be labeled as cancer? Curr Opin Urol. 2015 Feb 27. [Epub ahead of print]
Key words: gleason 6, cancer
http://www.ncbi.nlm.nih.gov/pubmed/25730327

5. Weingart MF, Roth JJ, Hutt-Cabezas M, Busse TM, Kaur H, Price A, Maynard R, Rubens J, Taylor I, Mao XG, Xu J, Kuwahara Y, Allen SJ, Erdreich-Epstein A, Weissman BE, Orr BA, Eberhart CG, Biegel JA, Raabe EH. Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target. Oncotarget. 2015 Feb 20;6(5):3165-77.
Key words: teratoid, mitogen, kinase, rhabdoid
http://www.ncbi.nlm.nih.gov/pubmed/25638158

1. Afsari B, Fertig EJ, Geman D, Marchionni L. switchBox: an R package for k Top Scoring Pairs classifier development. Bioinformatics. 2015 Jan 15;31(2):273-4. doi: 10.1093/bioinformatics/btu622. Epub 2014 Sep 26.
Key words: switchbox, classifier, development
http://www.ncbi.nlm.nih.gov/pubmed/25262153

2. Boleij A, Hechenbleikner EM, Goodwin AC, Badani R, Stein EM, Lazarev MG, Ellis B, Carroll KC, Albesiano E, Wick EC, Platz EA, Pardoll DM, Sears CL. The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin Infect Dis. 2015 Jan 15;60(2):208-15. doi: 10.1093/cid/ciu787..
Key words: colorectal cancer, mucosa, bacteroides
http://www.ncbi.nlm.nih.gov/pubmed/25305284

3. Chu NJ, Armstrong TD, Jaffee EM. Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention. Clin Cancer Res. 2015 Jan 26. pii: clincanres.1186.2014. [Epub ahead of print]
Key words: immunoprevention, antigens, inflammatory, signals
http://www.ncbi.nlm.nih.gov/pubmed/25623216

4. Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, Lutz ER, Solt S, Murphy AL, Skoble J, Lemmens E, Grous J, Dubensky T Jr, Brockstedt DG, Jaffee EM. Safety and survival with GVAX pancreas prime and listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015 Jan 12. pii: JCO.2014.57.4244. [Epub ahead of print]
Key words: listeria, pancreatic cancer, mesothelin
http://www.ncbi.nlm.nih.gov/pubmed/25584002

5. Stearns V, Chapman JA, Ma CX, Ellis MJ, Ingle JN, Pritchard KI, Budd GT, Rabaglio M, Sledge GW, Le Maitre A, Kundapur J, Liedke PE, Shepherd LE, Goss PE. Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial. J Clin Oncol. 2015 Jan 20;33(3):265-71. doi: 10.1200/JCO.2014.57.6926.
Key words: breast cancer, muscoskeletal, aromatase
http://www.ncbi.nlm.nih.gov/pubmed/25512454

6. Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, Luo J, Haffner MC, Yegnasubramanian S, Carducci MA, Eisenberger MA, Isaacs JT, Denmeade SR. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study. Sci Transl Med. 2015 Jan 7;7(269):269ra2. doi: 10.1126/scitranslmed.3010563.
Key words: prostate cancer, androgen therapy, asymptomatic
http://www.ncbi.nlm.nih.gov/pubmed/25568070

7. Wilky BA, Rudek MA, Ahmed S, Laheru DA, Cosgrove D, Donehower RC, Nelkin B, Ball D, Doyle LA, Chen H, Ye X, Bigley G, Womack C, Azad NS. A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours. Br J Cancer. 2015 Jan 6;112(1):24-31. doi: 10.1038/bjc.2014.515.
Key words: cituxumumab, selumetinib, inhibitor
http://www.ncbi.nlm.nih.gov/pubmed/25268371

1. Connolly RM, Leal JP, Goetz MP, Zhang Z, Zhou XC, Jacobs LK, Mhlanga J, O JH, Carpenter J, Storniolo AM, Watkins S, Fetting JH, Miller RS, Sideras K, Jeter SC, Walsh B, Powers P, Zorzi J, Boughey JC, Davidson NE, Carey LA, Wolff AC, Khouri N, Gabrielson E, Wahl RL, Stearns V. TBCRC 008: Early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer. J Nucl Med. 2015 Jan;56(1):31-7. doi: 10.2967/jnumed.114.144741.
Key words: breast cancer, PET, epidermal
http://www.ncbi.nlm.nih.gov/pubmed/25476537

2. Kanakry CG, Tsai HL, Bolaños-Meade J, Smith BD, Gojo I, Kanakry JA, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Powell JD, Pratz KW, DeZern AE, Showel MM, McDevitt MA, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. 2014 Dec 11;124(25):3817-27. doi: 10.1182/blood-2014-07-587477.
Key words: cyclophosphamide, myeloablative, GVHD
http://www.ncbi.nlm.nih.gov/pubmed/25316679

3. LeBeau AM, Denmeade SR. Protease-activated pore-forming peptides for the treatment and imaging of prostate cancer. Mol Cancer Ther. 2014 Dec 23. pii: molcanther.0744.2014. [Epub ahead of print]
Key words: prostate cancer, peptides, imaging
http://www.ncbi.nlm.nih.gov/pubmed/25537662

4. Mohseni M, Cidado J, Croessmann S, Cravero K, Cimino-Mathews A, Wong HY, Scharpf R, Zabransky DJ, Abukhdeir AM, Garay JP, Wang GM, Beaver JA, Cochran RL, Blair BG, Rosen DM, Erlanger B, Argani P, Hurley PJ, Lauring J, Park BH. MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers. Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17606-11. doi: 10.1073/pnas.1408650111.
Key words: estrogen, tamoxifen, breast cancer
http://www.ncbi.nlm.nih.gov/pubmed/25422431

5. Pollizzi KN, Powell JD. Regulation of T cells by mTOR: the known knowns and the known unknowns. Trends Immunol. 2015 Jan;36(1):13-20. doi: 10.1016/j.it.2014.11.005. Epub 2014 Dec 16. Review.
Key words: regulation, mTOR
http://www.ncbi.nlm.nih.gov/pubmed/25522665

6. Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, DeWeese TL, Drake CG. Stereotactic radiation therapy augments antigen-specific PD-1 mediated anti-tumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res. 2014 Dec 19. pii: canimm.0196.2014. [Epub ahead of print]
Key words: antigen, stereotactic, radiation
http://www.ncbi.nlm.nih.gov/pubmed/25527358

7. Stearns V, Chapman JA, Ma CX, Ellis MJ, Ingle JN, Pritchard KI, Budd GT, Rabaglio M, Sledge GW, Le Maitre A, Kundapur J, Liedke PE, Shepherd LE, Goss PE. Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial. J Clin Oncol. 2014 Dec 15. pii: JCO.2014.57.6926. [Epub ahead of print]
Key words: breast cancer, vasomotor, musculoskeletal

http://www.ncbi.nlm.nih.gov/pubmed/25512454

8. Tomasetti C, Marchionni L, Nowak MA, Parmigiani G, Vogelstein B. Only three driver gene mutations are required for the development of lung and colorectal cancers. Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):118-23. doi: 10.1073/pnas.1421839112. Epub 2014 Dec 22.
Key words: lung cancer, colorectal cancer, driver gene
http://www.ncbi.nlm.nih.gov/pubmed/25535351

9. Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Theriault RL, Hughes ME, Weeks JC, Karp JE. Risk of marrow neoplasms after adjuvant breast cancer therapy: The National Comprehensive Cancer Network Experience. J Clin Oncol. 2014 Dec 22. pii: JCO.2013.54.6119. [Epub ahead of print]
Key words: breast cancer, neoplasms, marrow
http://www.ncbi.nlm.nih.gov/pubmed/25534386

1. Bolaños-Meade J, Logan BR, Alousi AM, Antin JH, Barowski K, Carter SL, Goldstein SC, Hexner EO, Horowitz MM, Lee SJ, Levine JE, MacMillan ML, Martin PJ, Mendizabal AM, Nakamura R, Pasquini MC, Weisdorf DJ, Westervelt P, Ho VT. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood. 2014 Nov 20;124(22):3221-7. doi: 10.1182/blood-2014-06-577023.
Key words: mofetil, mycophenolate, steroids
http://www.ncbi.nlm.nih.gov/pubmed/25170121

2. Han L, Diehl A, Nguyen NK, Korangath P, Teo W, Cho S, Kominsky S, Huso DL, Feigenbaum L, Rein A, Argani P, Landberg G, Gessler M, Sukumar S. The Notch Pathway Inhibits TGF? Signaling in Breast Cancer through HEYL-Mediated Crosstalk. Cancer Res. 2014 Nov 15;74(22):6509-18. doi: 10.1158/0008-5472.CAN-14-0816. Epub 2014 Sep 12.
Key words: breast cancer, notch, crosstalk
http://www.ncbi.nlm.nih.gov/pubmed/25217524

3. Kang H, Kiess A, Chung CH. Emerging biomarkers in head and neck cancer in the era of genomics. Nat Rev Clin Oncol. 2014 Nov 18. doi: 10.1038/nrclinonc.2014.192. [Epub ahead of print] Review.
Key words: biomarkers, genomic, emerging
http://www.ncbi.nlm.nih.gov/pubmed/25403939

4. Mohseni M, Cidado J, Croessmann S, Cravero K, Cimino-Mathews A, Wong HY, Scharpf R, Zabransky DJ, Abukhdeir AM, Garay JP, Wang GM, Beaver JA, Cochran RL, Blair BG, Rosen DM, Erlanger B, Argani P, Hurley PJ, Lauring J, Park BH. MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers. Proc Natl Acad Sci U S A. 2014 Nov 24. pii: 201408650. [Epub ahead of print]
Key words: breast cancer, tamoxifen, estrogen, overexpression
http://www.ncbi.nlm.nih.gov/pubmed/25422431

5. Galanis A, Levis M. Inhibition of c-Kit by tyrosine kinase inhibitors. Haematologica. 2014 Nov 25. pii: haematol.2014.117028. [Epub ahead of print]
Key words: kinase, c-Kit, inhibitor
http://www.ncbi.nlm.nih.gov/pubmed/25425690

6. Ghosh S, Bhunia AK, Paun BC, Gilbert SF, Dhru U, Patel K, Kern SE. Genome Annotation by Shotgun Inactivation of a Native Gene in Hemizygous Cells: Application to BRCA2 with Implication of Hypomorphic Variants. Hum Mutat. 2014 Nov 29. doi: 10.1002/humu.22736. [Epub ahead of print]
Key words: hypomorphic, shotgun, BRCA2
http://www.ncbi.nlm.nih.gov/pubmed/25451944

7. Vendetti FP, Topper M, Huang P, Dobromilskaya I, Easwaran H, Wrangle J, Baylin SB, Poirier JT, Rudin CM. Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer. Oncotarget. 2014 Nov 25. [Epub ahead of print]
Key words: entinostat, lung cancer, cytotoxic
http://www.ncbi.nlm.nih.gov/pubmed/25474141

1. Dluzniewski PJ, Xu J, Ruczinski I, Isaacs WB, Platz EA. Polymorphisms influencing prostate specific antigen concentration may bias genome-wide association studies on prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014 Oct 28. pii: cebp.0863.2014. [Epub ahead of print]
Key words: polymorphisms, prostate cancer, bias, antigen
http://www.ncbi.nlm.nih.gov/pubmed/25352524

2. Drake CG, Sharma P, Gerritsen W. Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. Oncogene. 2014 Oct 23;33(43):5053-5064. doi: 10.1038/onc.2013.497. Epub 2013 Nov 25. Review.
Key words: immunotherapy, prostate cancer, novel combination
http://www.ncbi.nlm.nih.gov/pubmed/24276248

3. Huang TC, Renuse S, Pinto S, Kumar P, Yang Y, Chaerkady R, Godsey B, Mendell JT, Halushka MK, Civin CI, Marchionni L, Pandey A. Identification of miR-145 targets through an integrated omics analysis. Mol Biosyst. 2014 Oct 30. [Epub ahead of print]
Key words: omics, miR-145
http://www.ncbi.nlm.nih.gov/pubmed/25354783

4. Gojo I, Karp JE. new strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine. Clin Cancer Res. 2014 Oct 16. pii: clincanres.0900.2014. [Epub ahead of print]
Key words: leukemia, strategies, personalized
http://www.ncbi.nlm.nih.gov/pubmed/25324141

5. Kanakry CG, Tsai HL, Bolaños-Meade J, Smith BD, Gojo I, Kanakry JA, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Powell JD, Pratz KW, DeZern AE, Showel MM, McDevitt MA, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L. Post-transplantation cyclophosphamide as single-agent GVHD prophylaxis after myeloablative conditioning and HLA-matched allografting for acute leukemias and myelodysplastic syndrome. Blood. 2014 Oct 14. pii: blood-2014-07-587477. [Epub ahead of print]
Key words: leukemia, myelodysplastic, GVHD
http://www.ncbi.nlm.nih.gov/pubmed/25316679

6. Kanakry CG, Luznik L. Are alternative donors really still "alternative?" Biol Blood Marrow Transplant. 2014 Oct;20(10):1463-4. doi: 10.1016/j.bbmt.2014.07.029. Epub 2014 Jul 31.
Key words: alternative, donors
http://www.ncbi.nlm.nih.gov/pubmed/25087900

7. Lavorgna A, Harhaj EW. Regulation of HTLV-1 tax stability, cellular trafficking and NF-?B activation by the ubiquitin-proteasome pathway. Viruses. 2014 Oct 23;6(10):3925-3943. Review.
Key words: viruses, activation, HTLV-1
http://www.ncbi.nlm.nih.gov/pubmed/25341660

8. Llosa NJ, Cruise M, Tam A, Wick EC, Hechenbleikner EM, Taube JM, Blosser L, Fan H, Wang H, Luber B, Zhang M, Papadopoulos N, Kinzler KW, Vogelstein B, Sears CL, Anders RA, Pardoll DM, Housseau F. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2014 Oct 30. pii: CD-14-0863. [Epub ahead of print]
Key words: microsatellite, colon cancer, checkpoints
http://www.ncbi.nlm.nih.gov/pubmed/25358689

9. Reiss KA, Herman JM, Zahurak ML, Brade A, Dawson L, Scardina A, Joffe C, Petito E, Hacker-Prietz A, Kinders R, Wang L, Chen A, Temkin SM, Horiba N, Siu LL, Azad NA. A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis. Clin Cancer Res. 2014 Oct 29. pii: clincanres.1552.2014. [Epub ahead of print]
Key words: carcinomatosis, abdominal, veliparib, radiation therapy
http://www.ncbi.nlm.nih.gov/pubmed/25355929

10. Sison EA, Magoon D, Li L, Annesley CE, Rau RE, Small D, Brown P. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition. Oncotarget. 2014 Oct 15;5(19):8947-58.
Key words: leukemia, resistance, CXCR4
http://www.ncbi.nlm.nih.gov/pubmed/25333254

1. Bever KM, Sugar EA, Bigelow E, Sharma R, Laheru D, Wolfgang CL, Jaffee EM, Anders RA, De Jesus-Acosta A, Zheng L. The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy. HPB (Oxford). 2014 Sep 23. doi: 10.1111/hpb.12334. [Epub ahead of print]
Key words: stroma, pancreatic cancer, prognostic
http://www.ncbi.nlm.nih.gov/pubmed/25250696

2. Ganguly S, Ross DB, Panoskaltsis-Mortari A, Kanakry CG, Blazar BR, Levy RB, Luznik L. Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. Blood. 2014 Sep 25;124(13):2131-41. doi: 10.1182/blood-2013-10-525873.
Key words: Foxp3, protection, GVHD
http://www.ncbi.nlm.nih.gov/pubmed/25139358

3. Jones S, Stransky N, McCord CL, Cerami E, Lagowski J, Kelly D, Angiuoli SV, Sausen M, Kann L, Shukla M, Makar R, Wood LD, Diaz LA Jr, Lengauer C, Velculescu VE. Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. Nat Commun. 2014 Sep 19;5:5006. doi: 10.1038/ncomms6006.
Key words: chromatin, gynaecologic, mutations
http://www.ncbi.nlm.nih.gov/pubmed/25233892

4. Kanakry CG, O'Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M, Mielcarek M, Champlin RE, Jones RJ, Thall PF, Andersson BS, Luznik L. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014 Sep 29. pii: JCO.2013.54.0625. [Epub ahead of print]
Key words: bone marrow, cyclophosphamide, transplantation, allogeneic
http://www.ncbi.nlm.nih.gov/pubmed/25267759

5. Konig H, Levis M. Targeting FLT3 to treat leukemia. Expert Opin Ther Targets. 2014 Sep 18:1-18. [Epub ahead of print]
Key words: leukemia, treat, FLT3
http://www.ncbi.nlm.nih.gov/pubmed/25231999

6. Kumar A, Le DT. Hepatocellular carcinoma regression after cessation of immunosuppressive therapy. J Clin Oncol. 2014 Sep 22. pii: JCO.2013.51.4067. [Epub ahead of print]
Key words: regression, hepatocellular, carcinoma
http://www.ncbi.nlm.nih.gov/pubmed/2524544

7. Lopez DS, Peskoe SB, Tsilidis KK, Hoffman-Bolton J, Helzlsouer KJ, Isaacs WB, Smith MW, Platz EA. Association of variants in genes related to the immune response and obesity with BPH in CLUE II. Prostate Cancer Prostatic Dis. 2014 Sep 16. doi: 10.1038/pcan.2014.36. [Epub ahead of print]
Key words: prostate cancer, obesity, variants, genes
http://www.ncbi.nlm.nih.gov/pubmed/25224558

8. Richman LK, Zong JC, Latimer EM, Lock J, Fleischer R, Heaggans SY, Hayward GS. Elephant endotheliotropic herpesviruses EEHV1A, EEHV1B and EEHV2 from cases of hemorrhagic disease are highly diverged from other mammalian herpesviruses and may form a new subfamily. J Virol. 2014 Sep 17. pii: JVI.01673-14. [Epub ahead of print]
Key words: endotheliotropic, elephant, diverged, subfamily
http://www.ncbi.nlm.nih.gov/pubmed/25231303

9. Soares KC, Foley K, Olino K, Leubner A, Mayo SC, Jain A, Jaffee E, Schulick RD, Yoshimura K, Edil B, Zheng L. A preclinical murine model of hepatic metastases. J Vis Exp. 2014 Sep 27;(91). doi: 10.3791/51677.
Key words: hepatic, murine, metastases
http://www.ncbi.nlm.nih.gov/pubmed/25285458

10. Zong JC, Latimer EM, Long SY, Richman LK, Heaggans SY, Hayward GS. Comparative genome analysis of four elephant endotheliotropic herpesviruses EEHV3, EEHV4, EEHV5 and EEHV6 from cases of hemorrhagic disease or viremia. J Virol. 2014 Sep 17. pii: JVI.01675-14. [Epub ahead of print]
Key words: elephant, viremia, genome, analysis
http://www.ncbi.nlm.nih.gov/pubmed/25231309

1. Isaacs JT, Dalrymple SL, Rosen DM, Hammers H, Olsson A, Leanderson T. Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment. Oncotarget. 2014 Aug 21. [Epub ahead of print]
Key words: cancer, tasquinimod, albumin-binding, tumor
http://www.ncbi.nlm.nih.gov/pubmed/25193858

2. Maughan BL, Antonarakis ES. Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all. Asian J Androl. 2014 Aug 15. doi: 10.4103/1008-682X.137680. [Epub ahead of print]
Key words: enzalutamide, castration, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/25155108

3. Nadal R, Zhang Z, Rahman H, Schweizer MT, Denmeade SR, Paller CJ, Carducci MA, Eisenberger MA, Antonarakis ES. Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Prostate. 2014 Aug 31. doi: 10.1002/pros.22874. [Epub ahead of print]
Key words: enzalutamide, docetaxel, castration, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/25176007

4. Paller CJ, Bradbury PA, Ivy SP, Seymour L, LoRusso PM, Baker L, Rubinstein L, Huang E, Collyar D, Groshen S, Reeves S, Ellis LM, Sargent DJ, Rosner GL, LeBlanc ML, Ratain MJ. Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res. 2014 Aug 15;20(16):4210-4217. Review.
Key words: clinical trials, task force
http://www.ncbi.nlm.nih.gov/pubmed/25125258

5. Roberts NJ, Zhang L, Janku F, Collins A, Bai RY, Staedtke V, Rusk AW, Tung D, Miller M, Roix J, Khanna KV, Murthy R, Benjamin RS, Helgason T, Szvalb AD, Bird JE, Roy-Chowdhuri S, Zhang HH, Qiao Y, Karim B, McDaniel J, Elpiner A, Sahora A, Lachowicz J, Phillips B, Turner A, Klein MK, Post G, Diaz LA Jr, Riggins GJ, Papadopoulos N, Kinzler KW, Vogelstein B, Bettegowda C, Huso DL, Varterasian M, Saha S, Zhou S. Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Sci Transl Med. 2014 Aug 13;6(249):249ra111. doi: 10.1126/scitranslmed.3008982.
Key words: clostridium, injection, antitumor response
http://www.ncbi.nlm.nih.gov/pubmed/25122639

1. Brennen WN, Rosen DM, Chaux A, Netto GJ, Isaacs JT, Denmeade SR. Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer. Prostate. 2014 Jul 22. doi: 10.1002/pros.22847. [Epub ahead of print]
Key words: fibroblast, murine, toxicology
http://www.ncbi.nlm.nih.gov/pubmed/25053236

2. Cousins E, Gao Y, Sandford G, Nicholas J. Human herpesvirus 8 viral interleukin-6 signaling through gp130 promotes virus replication in primary effusion lymphoma and endothelial cells. J Virol. 2014 Jul 30. pii: JVI.01751-14. [Epub ahead of print]
Key words: replication, lymphoma, effusion
http://www.ncbi.nlm.nih.gov/pubmed/25078695

3. Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci U S A. 2014 Jul 28. pii: 201410626. [Epub ahead of print]
Key words: mouse, myeloid, metastatic, suppression
http://www.ncbi.nlm.nih.gov/pubmed/25071169

4. Ma HS, Nguyen B, Duffield AS, Li L, Galanis A, Williams AB, Brown PA, Levis MJ, Leahy DJ, Small D. FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia. Cancer Res. 2014 Jul 24. pii: canres.1028.2014. [Epub ahead of print]
Key words: leukemia, FLT3, TTT-3002
http://www.ncbi.nlm.nih.gov/pubmed/25060518

5. Suzman DL, Luber B, Schweizer MT, Nadal R, Antonarakis ES. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. Prostate. 2014 Jul 22. doi: 10.1002/pros.22844. [Epub ahead of print]
Key words: prostate cancer, docetaxel, enzalutamide
http://www.ncbi.nlm.nih.gov/pubmed/25053178

1. Antony L, van der Schoor F, Dalrymple SL, Isaacs JT. Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/?-catenin/TCF-4 complex inhibition of c-MYC transcription. Prostate. 2014 Aug;74(11):1118-31. doi: 10.1002/pros.22828. Epub 2014 Jun 9.
Key words: prostate cancer, androgen, epithelial
http://www.ncbi.nlm.nih.gov/pubmed/24913829

2. Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell. 2014 Jun 5;54(5):716-727. doi: 10.1016/j.molcel.2014.05.015. Review. PubMed
Key words: heterogeneity, epigenetics, plasticity
http://www.ncbi.nlm.nih.gov/pubmed/24905005

3. Holdhoff M, Ambady P, Abdelaziz A, Sarai G, Bonekamp D, Blakeley J, Grossman SA, Ye X. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology. 2014 Jun 13. pii: 10.1212/WNL.0000000000000593. [Epub ahead of print]
Key words: methotrexate, CNS, lymphoma
http://www.ncbi.nlm.nih.gov/pubmed/24928128

4. Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, Solt S, Dorman A, Wamwea A, Yager A, Laheru D, Wolfgang CL, Wang J, Hruban RH, Anders RA, Jaffee EM, Zheng L. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res. 2014 Jul;2(7):616-31. doi: 10.1158/2326-6066.CIR-14-0027. Epub 2014 Jun 18.
Key words: pancreatic cancer, foci, immunogenic
http://www.ncbi.nlm.nih.gov/pubmed/24942756

5. Pollizzi KN, Powell JD. Integrating canonical and metabolic signaling programmes in the regulation of T cell responses. Nat Rev Immunol. 2014 Jun 25;14(7):435-46. doi: 10.1038/nri3701.
Key words: canonical, metabolic, regulation
http://www.ncbi.nlm.nih.gov/pubmed/24962260

6. Sledge GW, Mamounas EP, Hortobagyi GN, Burstein HJ, Goodwin PJ, Wolff AC. Past, present, and future challenges in breast cancer treatment. J Clin Oncol. 2014 Jul 1;32(19):1979-86. doi: 10.1200/JCO.2014.55.4139. Epub 2014 Jun 2.
Key words: breast cancer, challeneges
http://www.ncbi.nlm.nih.gov/pubmed/24888802

7. Park JC, Pratz CF, Tesfaye A, Brodsky RA, Antonarakis ES. The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2014 Jun 11. pii: S1558-7673(14)00118-9. doi: 10.1016/j.clgc.2014.04.008. [Epub ahead of print]
Key words: prostate cancer, docetaxel, anticoagulation
http://www.ncbi.nlm.nih.gov/pubmed/24999166

8. Zeidner JF, Zahurak M, Rosner GL, Gocke CD, Jones RJ, Smith BD. The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions? Leuk Lymphoma. 2014 Jun 16:1-7. [Epub ahead of print]
Key words: leukemia, bone marrow, transplant
http://www.ncbi.nlm.nih.gov/pubmed/24712979

1. Cui Y, Hausheer F, Beaty R, Zahnow C, Issa JP, Bunz F, Baylin SB. A recombinant reporter system for monitoring reactivation of an endogenously DNA hypermethylated gene. Cancer Res. 2014 May 29. pii: canres.2287.2013. [Epub ahead of print]
Key words: hypermethylated, recombinant, reactivation
http://www.ncbi.nlm.nih.gov/pubmed/24876104

2. Eapen M, O'Donnell P, Brunstein CG, Wu J, Barowski K, Mendazibal A, Fuchs EJ. Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies. Biol Blood Marrow Transplant. 2014 May 23. pii: S1083-8791(14)00313-9. doi: 10.1016/j.bbmt.2014.05.015. [Epub ahead of print] Review.
Key words: allogeneic, heamatologic, donor, transplantation
http://www.ncbi.nlm.nih.gov/pubmed/24862638

3. Forde PM, Cochran RL, Boikos SA, Zabransky DJ, Beaver JA, Meyer CF, Thornton KA, Montgomery EA, Lidor AO, Donehower RC, Park BH. Familial GI stromal tumor with loss of heterozygosity and amplification of mutant KIT. J Clin Oncol. 2014 May 27. pii: JCO.2013.51.6633. [Epub ahead of print]
Key words: KIT, mutant, stromal, tumor
http://www.ncbi.nlm.nih.gov/pubmed/24868028

4. Gladstone DE, Davis-Sproul J, Campian J, Lemas MV, Malatyali S, Borrello I, King K, Grossman SA. Infusion of cryopreserved autologous lymphocytes using a standard peripheral i.v. catheter. Bone Marrow Transplant. 2014 May 19. doi: 10.1038/bmt.2014.98. [Epub ahead of print]
Key words: lymphocytes, catheter, cryopreserved
http://www.ncbi.nlm.nih.gov/pubmed/24842526

5. Guo H, Ma O, Friedman AD. The Cebpa +37-kb enhancer directs transgene expression to myeloid progenitors and to long-term hematopoietic stem cells. J Leukoc Biol. 2014 May 27. pii: jlb.2AB0314-145R. [Epub ahead of print]
Key words: transgene, enhancer, hematopoietic
http://www.ncbi.nlm.nih.gov/pubmed/24868087

6. Kuderer NM, Wolff AC. Enhancing therapeutic decision making when options abound: toxicities matter. J Clin Oncol. 2014 May 27. pii: JCO.2014.55.1903. [Epub ahead of print]
Key words: toxicity, options, decision
http://www.ncbi.nlm.nih.gov/pubmed/24868027

7. Lutz ER, Jaffee EM. Can we predict mutant neoepitopes in human cancers for patient-specific vaccine therapy? Cancer Immunol Res. 2014 Jun;2(6):518-21. doi: 10.1158/2326-6066.CIR-14-0041.
Key words: neoepitopes, vaccine, mutant
http://www.ncbi.nlm.nih.gov/pubmed/24795140

1. Almendro V, Kim HJ, Cheng YK, Gönen M, Itzkovitz S, Argani P, van Oudenaarden A, Sukumar S, Michor F, Polyak K. Genetic and phenotypic diversity in breast tumor metastases. Cancer Res. 2014 Mar 1;74(5):1338-48. doi: 10.1158/0008-5472.CAN-13-2357-T. Epub 2014 Jan 21.
Key words: breast tumor, diversity, genetic
http://www.ncbi.nlm.nih.gov/pubmed/24448237

2. Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, Rucki AA, Gunderson AJ, Coussens LM, Brockstedt DG, Dubensky TW Jr, Hassan R, Armstrong TD, Jaffee EM. A listeria vaccine and depletion of T-regulatory cells activate immunity against early-stage pancreatic intra-epithelial neoplasms and prolong survival of mice. Gastroenterology. 2014 Mar 6. pii: S0016-5085(14)00298-4. doi: 10.1053/j.gastro.2014.02.055. [Epub ahead of print]
Key words: listeria, neoplasms, vaccine
http://www.ncbi.nlm.nih.gov/pubmed/24607504

3. Kern SE, Sitzmann JV. Microvascular architecture in a case of gastric antral vascular ectasia (watermelon stomach). Am J Gastroenterol. 2014 Mar;109(3):449-51. doi: 10.1038/ajg.2013.449.
Key words: antral, watermelon, ectasia
http://www.ncbi.nlm.nih.gov/pubmed/24594964

4. Rucki AA, Zheng L. Pancreatic cancer stroma: Understanding biology leads to new therapeutic strategies. World J Gastroenterol. 2014 Mar 7;20(9):2237-2246. Review.
Key words: pancreatic cancer, stroma
http://www.ncbi.nlm.nih.gov/pubmed/24605023

5. Zabransky DJ, Park BH. Estrogen receptor and receptor tyrosine kinase signaling: use of combinatorial hormone and epidermal growth factor receptor/human epidermal growth factor receptor 2-targeted therapies for breast cancer. J Clin Oncol. 2014 Apr 1;32(10):1084-6. doi: 10.1200/JCO.2013.53.5070. Epub 2014 Mar 3.
Key words: tyrosine, breast cancer, epidermal
http://www.ncbi.nlm.nih.gov/pubmed/24590645

1. Cooke KR. A "window of opportunity" for patients with late-onset pulmonary dysfunction after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014 Jan 25. pii: S1083-8791(14)00024-X. doi: 10.1016/j.bbmt.2014.01.008. [Epub ahead of print]
Key words: Allogeneic, dysfunction, transplantation
http://www.ncbi.nlm.nih.gov/pubmed/24472717
Beumer JH, Venkataramanan R, Rudek MA. Pharmacotherapy in cancer patients with HIV/AIDS. Clin Pharmacol Ther. 2014 Jan 17. doi: 10.1038/clpt.2014.10. [Epub ahead of print]
Key words: HIV, pharmacotherapy
http://www.ncbi.nlm.nih.gov/pubmed/24440966

2. Forde PM, Kelly RJ, Brahmer JR. New strategies in lung cancer: translating immunotherapy into clinical practice. Clin Cancer Res. 2014 Jan 27. [Epub ahead of print]
Key words: immunotherapy, lung cancer
http://www.ncbi.nlm.nih.gov/pubmed/24470514

3. Joshu CE, Tsilidis KK, Peskoe SB, Giardiello FM, Dluzniewski PJ, Nelson WG, Iacobuzio-Donahue CA, Platz EA. The association between circulating high-sensitivity C-reactive protein concentration and pathologic measures of colonic inflammation. Cancer Causes Control. 2014 Jan 17. [Epub ahead of print]
Key words: colonic, C-reative, inflammation
http://www.ncbi.nlm.nih.gov/pubmed/24435936

4. Kanarek NF, Hooker CM, Mathieu L, Tsai HL, Rudin CM, Herman JG, Brock MV. Survival after community diagnosis of early stage non-small cell lung cancer. Am J Med. 2014 Jan 28. pii: S0002-9343(14)00073-4. doi: 10.1016/j.amjmed.2013.12.023. [Epub ahead of print]
Key words: lung cancer, survival, diagnosis
http://www.ncbi.nlm.nih.gov/pubmed/24486286

5. Park TS, Bhutto I, Zimmerlin L, Huo JS, Nagaria P, Miller D, Rufaihah AJ, Talbot C, Aguilar J, Grebe R, Merges C, Reijo-Pera R, Feldman RA, Rassool F, Cooke J, Lutty G, Zambidis ET. Vascular progenitors from cord blood-derived induced pluripotent stem cells possess augmented capacity for regenerating ischemic retinal vasculature. Circulation. 2014 Jan 21;129(3):359-72. doi: 10.1161/CIRCULATIONAHA.113.003000. Epub 2013 Oct 25.
Key words: retinal, stem cell, pluripotent, vasculature
http://www.ncbi.nlm.nih.gov/pubmed/24163065

6. Rudek MA, Moore PC, Mitsuyasu RT, Dezube BJ, Aboulafia D, Gerecitano J, Sullivan R, Cianfrocca ME, Henry DH, Ratner L, Haigentz M, Dowlati A, Little RF, Ivy SP, Deeken JF. A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. Cancer. 2014 Jan 28. doi: 10.1002/cncr.28554. [Epub ahead of print]
Key words: immunodeficienvy, sunitinib, antiretroviral
http://www.ncbi.nlm.nih.gov/pubmed/24474568

7. Schweizer MT, Drake CG. Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev. 2014 Jan 30. [Epub ahead of print]
Key words: prostate cancer, future, challenges
http://www.ncbi.nlm.nih.gov/pubmed/24477411

8. Schweizer MT, Zhou XC, Wang H, Bassi S, Carducci MA, Eisenberger MA, Antonarakis ES. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol. 2014 Jan 24. pii: S0302-2838(14)00069-4. doi: 10.1016/j.eururo.2014.01.018. [Epub ahead of print]
Key words: Abiraterone, docetaxel, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/24491307

9. Sun W, Gaykalova DA, Ochs MF, Mambo E, Arnaoutakis D, Liu Y, Loyo M, Agrawal N, Howard J, Li R, Ahn S, Fertig E, Sidransky D, Houghton J, Buddavarapu K, Sanford T, Choudhary A, Darden W, Adai A, Latham G, Bishop J, Sharma R, Westra WH, Hennessey P, Chung CH, Califano JA. Activation of the NOTCH pathway in head and neck cancer. Cancer Res. 2014 Jan 29. [Epub ahead of print]
Key words: NOTCH, activation, pathway
http://www.ncbi.nlm.nih.gov/pubmed/24351288

10. Sur S, Fries AC, Kinzler KW, Zhou S, Vogelstein B. Remote loading of preencapsulated drugs into stealth liposomes. Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2283-8. doi: 10.1073/pnas.1324135111. Epub 2014 Jan 28.
Key words: liposomes, preencapsulated, stealth
http://www.ncbi.nlm.nih.gov/pubmed/24474802

11. Tanno T, Lim Y, Wang Q, Chesi M, Bergsagel PL, Matthews G, Johnstone RW, Ghosh N, Borrello I, Huff CA, Matsui W. Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells. Blood. 2014 Jan 30;123(5):725-33. doi: 10.1182/blood-2013-08-524025. Epub 2013 Dec 17.
Key words: myeloma, factor 15
http://www.ncbi.nlm.nih.gov/pubmed/24345755

1. Bailey E, Li L, Duffield AS, Ma HS, Huso DL, Small D. FLT3/D835Y mutation knock-in mice display less aggressive disease compared with FLT3/internal tandem duplication (ITD) mice. Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21113-8. doi: 10.1073/pnas.1310559110.
Key words: aggressive, ITD, FLT3, mutation
http://www.ncbi.nlm.nih.gov/pubmed/24255108

2. Faisal F, Tsai HL, Blackford A, Olino K, Xia C, De Jesus-Acosta A, Le DT, Cosgrove D, Azad N, Rasheed Z, Diaz LA Jr, Donehower R, Laheru D, Hruban RH, Fishman EK, Edil BH, Schulick R, Wolfgang C, Herman J, Zheng L. Longer course of induction chemotherapy followed by chemoradiation favors better survival outcomes for patients with locally advanced pancreatic cancer. Am J Clin Oncol. 2013 Dec 17. [Epub ahead of print]
Key words: pancreatic cancer, induction, survival
http://www.ncbi.nlm.nih.gov/pubmed/24351782

3. Figueroa-Magalhães MC, Jelovac D, Connolly RM, Wolff AC. Treatment of HER2-positive breast cancer. Breast. 2013 Dec 18. pii: S0960-9776(13)00300-7. doi: 10.1016/j.breast.2013.11.011. [Epub ahead of print]
Key words: breast cancer, HER2, treatment
http://www.ncbi.nlm.nih.gov/pubmed/24360619

4. Sun W, Gaykalova DA, Ochs MF, Mambo E, Arnaoutakis D, Liu Y, Loyo M, Agrawal N, Howard J, Li R, Ahn S, Fertig E, Sidransky D, Houghton J, Buddavarapu K, Sanford T, Choudhary A, Darden W, Adai A, Latham G, Bishop J, Sharma R, Westra WH, Hennessey P, Chung CH, Califano JA. Activation of the NOTCH pathway in head and neck cancer. Cancer Res. 2014 Jan 29. [Epub ahead of print].
Key words: NOTCH, head and neck cancer, activation

http://www.ncbi.nlm.nih.gov/pubmed/24351288

5. Tanno T, Lim Y, Wang Q, Chesi M, Bergsagel PL, Matthews G, Johnstone RW, Ghosh N, Borrello I, Huff CA, Matsui W. Growth Differentiating Factor 15 enhances the tumor initiating and self-renewal potential of multiple myeloma cells. Blood. 2013 Dec 17. [Epub ahead of print]
Key words: factor 15, multiple myeloma
http://www.ncbi.nlm.nih.gov/pubmed/24345755

1. Armstrong AJ, Häggman M, Stadler WM, Gingrich JR, Assikis V, Polikoff J, Damber JE, Belkoff L, Nordle O, Forsberg G, Carducci MA, Pili R. Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013 Dec 15;19(24):6891-901.
Key words:prostate cancer, tasquinimod, multicenter randomized study
http://www.ncbi.nlm.nih.gov/pubmed/24255071

2. Bailey E, Li L, Duffield AS, Ma HS, Huso DL, Small D. FLT3/D835Y mutation knock-in mice display less aggressive disease compared with FLT3/internal tandem duplication (ITD) mice. Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21113-8.
Key words: FLT3, mutation, mice
http://www.ncbi.nlm.nih.gov/pubmed/24255108

3. Brahmer JR, Lee JW, Traynor AM, Hidalgo MM, Kolesar JM, Siegfried JM, Guaglianone PP, Patel JD, Keppen MD, Schiller JH. Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503). Eur J Cancer. 2013 Nov 15. doi:pii: S0959-8049(13)00932-5. 10.1016/j.ejca.2013.10.006. [Epub ahead of print]
Key words: lung cancer, erlotinib, phase II trial
http://www.ncbi.nlm.nih.gov/pubmed/24246704

4. Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol. 2014 Jan;11(1):24-37.
Key words: immunotherapy, melanoma, lung cancer, kidney cancer
PubMed PMID: 24247168.
http://www.ncbi.nlm.nih.gov/pubmed/24247168

5. Drake CG, Sharma P, Gerritsen W. Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. Oncogene. 2013 Nov 25. doi: 10.1038/onc.2013.497. [Epub ahead of print]
Key words: prostate cancer, immunotherapy
http://www.ncbi.nlm.nih.gov/pubmed/24276248

6. Galanis A, Ma H, Rajkhowa T, Ramachandran A, Small D, Cortes J, Levis M. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood. 2014 Jan 2;123(1):94-100.
Key words: cernolanib, FLT3, resistance
http://www.ncbi.nlm.nih.gov/pubmed/24227820

7. Joseph CG, Hwang H, Jiao Y, Wood LD, Kinde I, Wu J, Mandahl N, Luo J, Hruban RH, Diaz LA Jr, He TC, Vogelstein B, Kinzler KW, Mertens F, Papadopoulos N. Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas. Genes Chromosomes Cancer. 2014 Jan;53(1):15-24.
Key words: liposarcomas, osteosarcomas, synovial sarcomas
http://www.ncbi.nlm.nih.gov/pubmed/24190505

8. Kates M, Gorin MA, Deibert CM, Pierorazio PM, Schoenberg MP, McKiernan JM, Bivalacqua TJ. In-hospital death and hospital-acquired complications among patients undergoing partial cystectomy for bladder cancer in the United States. Urol Oncol. 2014 Jan;32(1):53.e9-53.e14.
Key words: cystectomy, bladder cancer, hospital-acquired complications
http://www.ncbi.nlm.nih.gov/pubmed/24239467

9. Le DT, Jaffee EM. Harnessing immune responses in the tumor microenvironment: all signals needed. Clin Cancer Res. 2013 Nov 15;19(22):6061-3.
Key words: immune response, tumor
http://www.ncbi.nlm.nih.gov/pubmed/24097857

10. Sharma D, Davidson NE. Obesity and breast cancer: a multipartite connection. J Mammary Gland Biol Neoplasia. 2013 Dec;18(3-4):253-5.
Key words: obesity, breast cancer
http://www.ncbi.nlm.nih.gov/pubmed/24190309

11. Zeidan AM, Forde PM, Symons H, Chen A, Smith BD, Pratz K, Carraway H, Gladstone DE, Fuchs EJ, Luznik L, Jones RJ, Bolaños-Meade J. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2013 Nov 29. doi:pii: S1083-8791(13)00557-0. 10.1016/j.bbmt.2013.11.020. [Epub ahead of print]
Key words: lymphocyte infusions, HLA, bone marrow transplantation
http://www.ncbi.nlm.nih.gov/pubmed/24296490

1. Campian J, Sarai G, Ye X, Marur S, Grossman SA. The association between severe treatment-related lymphopenia and progression free survival in patients with newly diagnosed squamous cell head and neck cancer. Head Neck. 2013 Oct 31. doi: 10.1002/hed.23535. [Epub ahead of print]
Key words: lymphopenia, head and neck cancer
http://www.ncbi.nlm.nih.gov/pubmed/24174270

2. Forde PM, Reiss KA, Zeidan AM, Brahmer JR. What lies within: novel strategies in immunotherapy for non-small cell lung cancer. Oncologist. 2013 Oct 8. [Epub ahead of print]
Key words: lung cancer, immunotherapy
http://www.ncbi.nlm.nih.gov/pubmed/24105749

3. Paller CJ, Olatoye D, Xie S, Zhou X, Denmeade SR, Eisenberger MA, Antonarakis ES, Carducci MA, Rosner GL. The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2013 Oct 8. doi: 10.1038/pcan.2013.40. [Epub ahead of print]
Key words: prostate cancer, PSA, biochemical
http://www.ncbi.nlm.nih.gov/pubmed/24100642

4. Papadopoulos N, Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg MP, Bivalacqua T, Allaf ME, Springer S, Wang Y, Diaz LA Jr, Kinzler KW, Vogelstein B, Netto GJ. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res. 2013 Oct 11. [Epub ahead of print]
Key words: urothelial, urine, neoplasia, biomarkers
http://www.ncbi.nlm.nih.gov/pubmed/24121487

5. Suzman DL, Eisenberger MA. Determining the optimal treatment for metastatic castration-resistant prostate cancer: age should not be a factor. Eur Urol. 2013 Oct 16. doi:pii: S0302-2838(13)01075-0. 10.1016/j.eururo.2013.10.002. [Epub ahead of print]
Key words: metastatic, castration, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/24157242

6. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Arch Pathol Lab Med. 2013 Oct 7. [Epub ahead of print]
Key words: breast cancer, epidermal
http://www.ncbi.nlm.nih.gov/pubmed/24099077

7. Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, Vancriekinge W, Demeyer T, Du Z, Parsana P, Rodgers K, Yen RW, Zahnow CA, Taube JM, Brahmer JR, Tykodi SS, Easton K, Carvajal RD, Jones PA, Laird PW, Weisenberger DJ, Tsai S, Juergens RA, Topalian SL, Rudin CM, Brock MV, Pardoll D, Baylin SB. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget. 2013 Oct 25. [Epub ahead of print]
Key words: lung cancer, azacytine, immune
http://www.ncbi.nlm.nih.gov/pubmed/24162015

9. Yang X, Sexauer A, Levis M. Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase. Br J Haematol. 2013 Oct 10. doi: 10.1111/bjh.12599. [Epub ahead of print]
Key words: stroma, FLT3, extracellular
http://www.ncbi.nlm.nih.gov/pubmed/24116827

1. Chung CH, Bagheri A, D'Souza G. Epidemiology of oral human papillomavirus infection. Oral Oncol. 2013 Sep 27. doi:pii: S1368-8375(13)00685-4. 10.1016/j.oraloncology.2013.09.003. [Epub ahead of print]
Key words: epidemiology, papillomavirus
http://www.ncbi.nlm.nih.gov/pubmed/24080455

2. Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong RC, James J, Levis M. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013 Oct 10;31(29):3681-3687.
Key words: leukemia, duplication, myeloid
http://www.ncbi.nlm.nih.gov/pubmed/24002496

3. Ghiaur G, Yegnasubramanian S, Perkins B, Gucwa JL, Gerber JM, Jones RJ. Regulation of human hematopoietic stem cell self-renewal by the microenvironment's control of retinoic acid signaling. Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16121-16126.
Key words: hematopoietic, retinoic acid
http://www.ncbi.nlm.nih.gov/pubmed/24043786

4. Murray-Stewart T, Hanigan CL, Woster PM, Marton LJ, Casero RA Jr. Histone deacetylase inhibition overcomes drug resistance through a miRNA-dependent mechanism. Mol Cancer Ther. 2013 Sep 26. [Epub ahead of print]
Key words: miRNA, deacetylase
http://www.ncbi.nlm.nih.gov/pubmed/23943804

5. Nirschl CJ, Drake CG. Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res. 2013 Sep 15;19(18):4917-24. doi: 10.1158/1078-0432.CCR-12-1972.
Key words: checkpoint, molecules, immunotherapy
http://www.ncbi.nlm.nih.gov/pubmed/23868869

6. Klein AP, Lindström S, Mendelsohn JB, Steplowski E, Arslan AA, Bueno-de-Mesquita HB, Fuchs CS, Gallinger S, Gross M, Helzlsouer K, Holly EA, Jacobs EJ, Lacroix A, Li D, Mandelson MT, Olson SH, Petersen GM, Risch HA, Stolzenberg-Solomon RZ, Zheng W, Amundadottir L, Albanes D, Allen NE, Bamlet WR, Boutron-Ruault MC, Buring JE, Bracci PM, Canzian F, Clipp S, Cotterchio M, Duell EJ, Elena J, Gaziano JM, Giovannucci EL, Goggins M, Hallmans G, Hassan M,Hutchinson A, Hunter DJ, Kooperberg C, Kurtz RC, Liu S, Overvad K, Palli D, Patel AV, Rabe KG, Shu XO, Slimani N, Tobias GS, Trichopoulos D, Van Den Eeden SK, Vineis P, Virtamo J, Wactawski-Wende J, Wolpin BM, Yu H, Yu K,
Zeleniuch-Jacquotte A, Chanock SJ, Hoover RN, Hartge P, Kraft P. An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population. PLoS One. 2013 Sep 13;8(9):e72311. doi: 10.1371/journal.pone.0072311.
Key words: pancreatic cancer, absolute, risk
http://www.ncbi.nlm.nih.gov/pubmed/24058443

7. Sharma D, Sukumar S. Big Punches Come in Nanosizes for Chemoprevention. Cancer Prev Res (Phila). 2013 Oct;6(10):1007-1010.
Key words: nanosizes, chemoprevention
http://www.ncbi.nlm.nih.gov/pubmed/24072677

8. Shaw PG, Chaerkady R, Wang T, Vasilatos S, Huang Y, Van Houten B, Pandey A, Davidson NE. Integrated proteomic and metabolic analysis of breast cancer progression. PLoS One. 2013 Sep 27;8(9):e76220.
Key words: breast cancer, proteomic
http://www.ncbi.nlm.nih.gov/pubmed/24086712

9. Wada S, Harris TJ, Tryggestad E, Yoshimura K, Zeng J, Yen HR, Getnet D, Grosso JF, Bruno TC, De Marzo AM, Netto GJ, Pardoll DM, Deweese TL, Wong J, Drake CG. Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer model. Int J Radiat Oncol Biol Phys. 2013 Sep 21. doi:pii: S0360-3016(13)02853-8. 10.1016/j.ijrobp.2013.07.015. [Epub ahead of print]
Key words: prostate cancer, autochtonous, immunotherapy
http://www.ncbi.nlm.nih.gov/pubmed/24064321

1. Brennen WN, Denmeade SR, Isaacs JT. Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocr Relat Cancer. 2013 Aug 23;20(5):R269-90. doi: 10.1530/ERC-13-0151. Print 2013.
Key words: mesenchymal, microenvironment, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/23975882

2. Di Cello F, Flowers VL, Li H, Vecchio-Pagán B, Gordon B, Harbom K, Shin J, Beaty R, Wang W, Brayton C, Baylin SB, Zahnow CA. Cigarette smoke induces epithelial to mesenchymal transition and increases the metastatic ability of breast cancer cells. Mol Cancer. 2013 Aug 6;12:90. doi: 10.1186/1476-4598-12-90.
Key words: smoke, mesenchymal, breast cancer
http://www.ncbi.nlm.nih.gov/pubmed/23919753

3. Fu C, van der Zwan A, Gerber S, Van Den Berg S, No E, C H Wang W, Sheibani N, Carducci MA, Kachhap S, Hammers HJ. Screening assay for blood vessel maturation inhibitors. Biochem Biophys Res Commun. 2013 Aug 23;438(2):364-9. doi: 10.1016/j.bbrc.2013.07.077. Epub 2013 Jul 25.
Key words: inhibitor, blood vessel, maturation
http://www.ncbi.nlm.nih.gov/pubmed/23892038

4. Fuchs EJ. Selective allodepletion: have we finally found the holy grail? Biol Blood Marrow Transplant. 2013 Aug 13. doi:pii: S1083-8791(13)00353-4. 10.1016/j.bbmt.2013.08.004. [Epub ahead of print]
Key words: allodepletion, holy grail
http://www.ncbi.nlm.nih.gov/pubmed/23954761

5. Murray-Stewart T, Hanigan CL, Woster PM, Marton LJ, Casero RA. Histone deacetylase inhibition overcomes drug resistance through a miRNA-dependent mechanism. Mol Cancer Ther. 2013 Aug 13. [Epub ahead of print]
Key words: miRNA, deacetylase, inhibition
http://www.ncbi.nlm.nih.gov/pubmed/23943804

6. Rangachari D, Brahmer JR. Targeting the immune system in the treatment of non-small-cell lung cancer. Curr Treat Options Oncol. 2013 Aug 11. [Epub ahead of print]
Key words: lung cancer, immune, targeting
http://www.ncbi.nlm.nih.gov/pubmed/23934510

7. Schweizer MT, Huang P, Kattan MW, Kibel AS, de Wit R, Sternberg CN, Epstein JI, Eisenberger MA. Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): Important lessons for future trials. Cancer. 2013 Aug 13. doi: 10.1002/cncr.28270. [Epub ahead of print]
Key words: docetaxel, prostate cancer, leuprolide
http://www.ncbi.nlm.nih.gov/pubmed/23943299

8. Schweizer MT, Lin J, Blackford A, Bardia A, King S, Armstrong AJ, Rudek MA, Yegnasubramanian S, Carducci MA. Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2013 Aug 20. doi: 10.1038/pcan.2013.28. [Epub ahead of print]
Key words: disulfiram, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/23958896

9. Smith BD, Mahmoud D, Dacosta-Byfield S, Rosen VM. Health care utilization and risk of infection and bleeding among patients with myelodysplastic syndromes with/without transfusions, and with/without active therapy. Leuk Lymphoma. 2013 Aug 28. [Epub ahead of print]
Key words: myelodysplastic, infection, bleeding
http://www.ncbi.nlm.nih.gov/pubmed/23841504

10. Thornton KA, Chen AR, Trucco MM, Shah P, Wilky BA, Gul N, Carrera-Haro MA, Ferreira MF, Shafique U, Powell JD, Meyer CF, Loeb DM. A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma. Int J Cancer. 2013 Aug 15;133(4):997-1005. doi: 10.1002/ijc.28083. Epub 2013 Mar 4.
Key words: temsirolimus, doxorubicin, sarcoma
http://www.ncbi.nlm.nih.gov/pubmed/23382028

11. Yang J, Hendricks W, Liu G, McCaffery JM, Kinzler KW, Huso DL, Vogelstein B, Zhou S. A nanoparticle formulation that selectively transfects metastatic tumors in mice. Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14717-22. doi: 10.1073/pnas.1313330110. Epub 2013 Aug 19.
Key words: nanoparticle, mice, tumors
http://www.ncbi.nlm.nih.gov/pubmed/23959886

12. Zeidan AM, Gore SD, McNally DL, Baer MR, Hendrick F, Mahmoud D, Davidoff AJ. Lenalidomide
performance in the real world: Patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes. Cancer. 2013 Aug 6. doi: 10.1002/cncr.28298. [Epub ahead of print]
Key words: myelodysplastic, lenalidomide
http://www.ncbi.nlm.nih.gov/pubmed/23922173

1. Beaver JA, Gustin JP, Yi KH, Rajpurohit A, Thomas M, Gilbert SF, Rosen DM, Park BH, Lauring J. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system. Clin Cancer Res. 2013 Jul 25. [Epub ahead of print]
Key words: isogenic, inhibitors, breast cancer
http://www.ncbi.nlm.nih.gov/pubmed/23888070

2. Fu C, van der Zwan A, Gerber S, Van Den Berg S, No E, Wang W, Sheibani N, Carducci MA, Kachhap S, Hammers HJ. Screening assay for blood vessel maturation inhibitors. Biochem Biophys Res Commun. 2013 Jul 25. doi:pii: S0006-291X(13)01239-4. 10.1016/j.bbrc.2013.07.077. [Epub ahead of print]
Key words: screening, blood vessel, inhibitors
http://www.ncbi.nlm.nih.gov/pubmed/23892038

3. Gantt S, Casper C, Ambinder RF. Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention. Curr Opin Oncol. 2013 Jul 18. [Epub ahead of print]
Key words: nelfinavir, HIV, inhibitors
http://www.ncbi.nlm.nih.gov/pubmed/23872785

4. Herman JM, Fan KY, Wild AT, Hacker-Prietz A, Wood LD, Blackford AL, Ellsworth S, Zheng L, Le DT, De Jesus-Acosta A, Hidalgo M, Donehower RC, Schulick RD, Edil BH, Choti MA, Hruban RH, Pawlik TM, Cameron JL, Laheru DA, Wolfgang CL. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):678-85. doi: 10.1016/j.ijrobp.2013.03.032.
Key words: erlotinib, pancreatic cancer, chemotherapy
http://www.ncbi.nlm.nih.gov/pubmed/23773391

5. Kortenhorst MS, Wissing MD, Rodríguez R, Kachhap SK, Jans JJ, Van der Groep P, Verheul HM, Gupta A, Aiyetan PO, van der Wall E, Carducci MA, Van Diest PJ, Marchionni L. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors. Epigenetics. 2013 Jul 19;8(9). [Epub ahead of print]
Key words: deacetylase, prostate cancer, histone
http://www.ncbi.nlm.nih.gov/pubmed/23880963

6. Pelosof L, Yerram SR, Ahuja N, Delmas A, Danilova L, Herman JG, Azad NS. CHFR silencing or microsatellite instability is associated with increased anti-tumor activity of docetaxel or gemcitabine in colorectal cancer. Int J Cancer. 2013 Jul 20. doi: 10.1002/ijc.28390. [Epub ahead of print]
Key words: colorectal cancer, docetaxel, instability
http://www.ncbi.nlm.nih.gov/pubmed/23873170

7. Poirier JT, Dobromilskaya I, Moriarty WF, Peacock CD, Hann CL, Rudin CM. Selective tropism of seneca valley virus for variant subtype small cell lung cancer. J Natl Cancer Inst. 2013 Jul 17;105(14):1059-65. doi: 10.1093/jnci/djt130. Epub 2013 Jun 5.
Key words: tropism, Seneca valley, lung cancer
PubMed PMID: 23739064.
http://www.ncbi.nlm.nih.gov/pubmed/23739064

8. Ray Banerjee S, Pullambhatla M, Foss CA, Falk A, Byun Y, Nimmagadda S, Mease RC, Pomper MG. Effect of Chelators on the Pharmacokinetics of (99m)Tc-Labeled Imaging Agents for the Prostate-Specific Membrane Antigen (PSMA). J Med Chem. 2013 Jul 22. [Epub ahead of print]
Key words: antigen, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/23799782

9. Stearns V, Jacobs LK, Fackler M, Tsangaris TN, Rudek MA, Higgins M, Lange J, Cheng Z, Slater SA, Jeter SC, Powers P, Briest S, Chao C, Yoshizawa C, Sugar E, Espinoza-Delgado I, Sukumar S, Gabrielson E, Davidson NE. Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast Cancer. Clin Cancer Res. 2013 Jul 15;19(14):4008-16. doi: 10.1158/1078-0432.CCR-13-0033. Epub 2013 May 29.
Key words: vorinostat, breast cancer
http://www.ncbi.nlm.nih.gov/pubmed/23719261

10. Vendetti FP, Rudin CM. Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases. Expert Opin Biol Ther. 2013 Jul 17. [Epub ahead of print]
Key words: DNA, epigenetic, lung cancer
http://www.ncbi.nlm.nih.gov/pubmed/23859704

1. Haffner MC, Pellakuru LG, Ghosh S, Lotan TL, Nelson WG, De Marzo AM, Yegnasubramanian S. Tight correlation of 5-hydroxymethylcytosine and Polycomb marks in health and disease. Cell Cycle. 2013 Jun 15;12(12):1835-41. doi: 10.4161/cc.25010. Epub 2013 May 15.
Key words: polycomb, correlation
http://www.ncbi.nlm.nih.gov/pubmed/23676216

2. Howard JD, Moriarty WF, Park J, Riedy K, Panova IP, Chung CH, Suh KY, Levchenko A, Alani RM. Notch signaling mediates melanoma-endothelial cell communication and melanoma cell migration. Pigment Cell Melanoma Res. 2013 Jun 16. doi: 10.1111/pcmr.12131. [Epub ahead of print]
Key words: melanoma, endothelial
http://www.ncbi.nlm.nih.gov/pubmed/23773728

3. Jeschke J, O'Hagan HM, Zhang W, Vatapalli R, Calmon MF, Danilova L, Nelkenbrecher C, Van Neste L, Bijsmans IT, Van Engeland M, Gabrielson E, Schuebel KE, Winterpacht A, Baylin SB, Herman JG, Ahuja N. Frequent inactivation of cysteine dioxygenase type 1 contributes to survival of breast cancer cells and resistance to anthracyclines. Clin Cancer Res. 2013 Jun 15;19(12):3201-11. doi: 10.1158/1078-0432.CCR-12-3751. Epub 2013 Apr 29.
Key words: dioxygenase, breast cancer, anthracyclines
http://www.ncbi.nlm.nih.gov/pubmed/23630167

4. Kanakry JA, Ambinder RF. EBV-related lymphomas: new approaches to treatment. Curr Treat Options Oncol. 2013 Jun;14(2):224-36. doi: 10.1007/s11864-013 0231-y. PubMed PMID: 23549980; PubMed Central
Key words: EBV, lymphoma
http://www.ncbi.nlm.nih.gov/pubmed/23549980

5. Kostova MB, Rosen DM, Chen Y, Mease RC, Denmeade SR. Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors. J Med Chem. 2013 Jun 13;56(11):4224-35. doi: 10.1021/jm301718c. Epub 2013 Jun 4.
Key words: prostate cancer, peptidomimetic
http://www.ncbi.nlm.nih.gov/pubmed/23692593

6. Michiel Sedelaar JP, Dalrymple SS, Isaacs JT. Of mice and men-warning: Intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectively. Prostate. 2013 Jun 15. doi: 10.1002/pros.22677. [Epub ahead of print]
Key words: abiraterone, hypogonadal, xenograft, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/23775398

7. Nadal R, McMahan ZH, Antonarakis ES. Paraneoplastic palmar fasciitis and polyarthritis syndrome in a patient with advanced prostate cancer. Clin Genitourin Cancer. 2013 Jun 29. doi:pii: S1558-7673(13)00139-0. 10.1016/j.clgc.2013.05.008. [Epub ahead of print]
Key words: prostate cancer, genitourin, fasciitis
http://www.ncbi.nlm.nih.gov/pubmed/23820064

8. Poirier JT, Dobromilskaya I, Moriarty WF, Peacock CD, Hann CL, Rudin CM. Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer. J Natl Cancer Inst. 2013 Jun 5. [Epub ahead of print]
Key words: tropism, senca valley
http://www.ncbi.nlm.nih.gov/pubmed/23739064

9. Sison EA, McIntyre E, Magoon D, Brown P. Dynamic chemotherapy-induced upregulation of surface CXCR4 expression as a mechanism of chemotherapy resistance in pediatric acute myeloid leukemia. Mol Cancer Res. 2013 Jun 10. [Epub ahead of print]
Key words: CXCR4, leukemia, chemotherapy
http://www.ncbi.nlm.nih.gov/pubmed/23754844

10. Stearns V, Jacobs LK, Fackler M, Tsangaris TN, Rudek MA, Higgins M, Lange J, Cheng Z, Slater SA, Jeter SC, Powers P, Briest S, Chao C, Yoshizawa C, Sugar E, Espinoza-Delgado I, Sukumar S, Gabrielson E, Davidson NE. Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer. Clin Cancer Res. 2013 Jun 27. [Epub ahead of print]
Key words: breast cancer, vorinostat
http://www.ncbi.nlm.nih.gov/pubmed/23719261

11. Wang GM, Wong HY, Konishi H, Blair BG, Abukhdeir AM, Gustin JP, Rosen DM, Denmeade SR, Rasheed Z, Matsui W, Garay JP, Mohseni M, Higgins MJ, Cidado J, Jelovac D, Croessmann S, Cochran RL, Karnan S, Konishi Y, Ota A, Hosokawa Y, Argani P, Lauring J, Park BH. Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. Cancer Res. 2013 Jun 1;73(11):3248-61. doi: 10.1158/0008-5472.CAN-12-1578. Epub 2013 Apr 11.
Key words: PIK3CA, epithelial, immortalize
PubMed PMID: 23580570; PubMed Central PMCID: PMC3674106.
http://www.ncbi.nlm.nih.gov/pubmed/23580570

Return to top of Publications - Oncology Archives


Search Publications
 
   
May 2016 articles:
Johns Hopkins Research Network
JHM HSR Recertification Training
JHM OHSR Compliance Monitoring Program Educational Seminar Series
 
Visit Animal Care and Use Committee Website
Current Classes
"Interinstitutional Assurance" Agreement
Health, Safety, and Environment (HSE) presents: Safety in Research Updates
American Diabetes Association (ADA) Program: Pathway to Stop Diabetes
Department of Defense Multiple Sclerosis Research Program (MSRP)
Under Armour Women's Health & Breast Cancer Innovation Grant
W. W. Smith Charitable Trust Program: Heart Disease, Cancer, and AIDS Research
Harrington Scholar-Innovator Award
Department of Defense Peer Reviewed Cancer Research Program (PRCRP)
Edward Mallinckrodt, Jr. Foundation Research Grants
Lupus Research Institute - New Research Grants for Novel Approaches To Lupus
Lupus Research Institute - Dr. William E. Paul Distinguished Innovator Awards in Lupus and Autoimmunity
Research Participant Financial Responsibility Information Sheet
NIH Policy: Foreign Components Added to a Grant to a Domestic or Foreign Organization

This Month's Departmental Listings

Upcoming Deadlines for May and June

May Events at the Genetic Resources Core Facility
       

 

JHM AppointmentsEmployment @ JHM | Finding a Doctor | Disclaimer | Maps & Directions | Contact JHM 

 

                                                                                                                                                           The Web Center